

CITATION REPORT

List of articles citing

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

DOI: 10.1056/nejmoa040720

New England Journal of Medicine, 2004, 351, 1502-12.

Source: <https://exaly.com/paper-pdf/37444315/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2245	Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. 1994 , 20, 891		2
2244	Palliative systemic antineoplastic therapy. 2001 , 399-420		
2243	Management of androgen-independent prostate cancer. 2004 , 11, 364-73		37
2242	Mechanisms of androgen-refractory prostate cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 1488-90	39.2	451
2241	Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 1513-20	59.2	2893
2240	Atrasentan: targeting the endothelin axis in prostate cancer. 2004 , 13, 1631-40		30
2239	Chemotherapy for patients with hormone-refractory prostate cancer. 2004 , 15, 1582-4		11
2238	Early use of chemotherapy in conjunction with radical prostatectomy. 2004 , 3, 144-9		3
2237	Angiogenesis-targeted therapies in prostate cancer. 2004 , 3, 165-73		25
2236	Docetaxel in advanced prostate cancer. 2004 , 1, 62-62		
2235	Update in the management of patients with hormone-refractory prostate cancer. 2005 , 15, 157-62		10
2234	Progress in detection and treatment of prostate cancer. 2005 , 17, 257-60		2
2233	Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?. 2005 , 2, 18-19		
2232	In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment. 2005 , 16, 417-22		18
2231	Chemotherapy for metastatic disease: current status. 2005 , 17, 572-8		2
2230	Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. 2005 , 1058, 1-15		36
2229	A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. 2005 , 95, 963-8		15

2228	Prolonging survival in prostate cancer: chemotherapy will have an important role. 2005 , 96, 2-3	
2227	Epothilones and the next generation of phase III trials for prostate cancer. 2005 , 96, 296-302	22
2226	ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. 2005 , 96, 508-13	39
2225	Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer. 2005 , 96, 640-6	7
2224	A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. 2005 , 96, 787-90	10
2223	Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. 2005 , 96, 791-5	53
2222	The immunotherapy of prostate and bladder cancer. 2005 , 96, 728-35	12
2221	A retrospective study of the time to clinical endpoints for advanced prostate cancer. 2005 , 96, 985-9	88
2220	Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. 2005 , 96, 1241-6	155
2219	Therapeutic options in androgen-independent prostate cancer: building on docetaxel. 2005 , 96 Suppl 2, 41-6	44
2218	Design of clinical trials in advanced prostate cancer: avoiding the dead ends. 2005 , 96 Suppl 2, 47-53	1
2217	Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. 2005 , 12, 785-94	45
2216	Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. 2005 , 12, 1012-3	22
2215	Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer. 2005 , 35, 405-8	4
2214	Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. 2005 , 35, 468-72	11
2213	Prostate epithelial stem cells. 2005 , 38, 363-74	86
2212	Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. 2005 , 93, 633-8	56
2211	Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. 2005 , 47, 449-54; discussion 454-5	72

2210	Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. 2005 , 48, 771-5; discussion 775-8	24
2209	What's new in urology. 2005 , 201, 438-48	2
2208	Advances in prostate cancer chemotherapy: a new era begins. 2005 , 55, 300-18; quiz 323-5	128
2207	A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. 2005 , 96, 439-46	32
2206	Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. 2005 , 56 Suppl 1, 47-57	36
2205	Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes. 2005 , 56 Suppl 1, 69-77	2
2204	Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. 2005 , 23, 38-46	84
2203	Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. 2005 , 23, 33-7	15
2202	Chemotherapy for androgen-independent prostate cancer. 2005 , 23, 10-3	19
2201	Cancer of the prostate. 2005 , 56, 379-96	78
2200	Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. 2005 , 10, 182-6	10
2199	Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. 2005 , 10, 333-7	10
2198	Intérêt des voies de signalisation EGFR et PDGFR dans le traitement des métastases osseuses du cancer de la prostate hormono-résistant. 2005 , 7, 387-390	
2197	Biologie de la transition vers l'hormono-résistance des cancers de la prostate. 2005 , 7, 391-396	
2196	Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. 2005 , 7, 220-7	11
2195	Secondary hormonal manipulations in prostate cancer. 2005 , 7, 228-33	12
2194	Local and systemic therapy for patients with metastatic prostate cancer: Should the primary tumor be treated?. 2005 , 3, 153-159	1
2193	Chemotherapy agents and timing of chemotherapy in prostate cancer management. 2005 , 3, 58-61	

2192	Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?. 2005 , 6, 183-9	9
2191	Chemotherapy agents and timing of chemotherapy in prostate cancer management. 2005 , 6, 224-7	
2190	Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. 2005 , 65, 141-50	26
2189	Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. 2005 , 65, 178-87	74
2188	Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer. 2005 , 65, 316-21	1
2187	[The action and toxicity of taxanes]. 2005 , 34, 128-37	2
2186	Glucose Metabolism of Human Prostate Cancer Mouse Xenografts. 2005 , 4, 153535002005051	30
2185	Esmo 2004 Studi Di Confronto Che Delineano le Opzioni Future Nel Trattamento Dei Tumori Solidi. 2005 , 91, 21-35	
2184	Dose-Finding Study of Weekly Docetaxel plus Estramustine in Patients with Hormone-Refractory Metastatic Prostate Cancer. 2005 , 91, 314-316	2
2183	Case study: management of advanced prostate cancer with soft tissue metastases. 2005 , 8, 290-2	5
2182	Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies. 2005 , 44, 610-27	9
2181	Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer. 2005 , 8, 364-8	10
2180	Second Acta Oncologia symposium on prostate cancer controversies. 2005 , 44, 526-8	1
2179	Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?. 2005 , 2, 70-1	2
2178	Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?". 2005 , 23, 8242-6	30
2177	High-risk localized prostate cancer: integrating chemotherapy. 2005 , 10 Suppl 2, 18-22	11
2176	Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. 2005 , 11, 4905-11	51
2175	Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. 2005 , 23, 1439-46	168

2174	Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. 2005 , 10 Suppl 3, 30-9	29
2173	Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. 2005 , 11, 3210-6	109
2172	A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. 2005 , 11, 6625-33	137
2171	Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. 2005 , 11, 5233-40	151
2170	Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. 2005 , 23, 2918-25	353
2169	Prostate cancer chemotherapy: emerging from the shadows. 2005 , 23, 3302-3	11
2168	Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. 2005 , 23, 8232-41	121
2167	Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. 2005 , 23, 8225-31	55
2166	Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. 2005 , 16, 419-24	11
2165	What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer?. 2005 , 23, 3304-7	3
2164	The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. 2005 , 4, 14-22	178
2163	Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. 2005 , 12, 109-17	101
2162	Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. 2005 , 11, 3743-9	41
2161	Phase III trials in oncology: setting standards of care?. 2005 , 2, 426-7	3
2160	[Therapy of hormone refractory prostate cancer: new standards, new trends]. 2005 , 36, 342-8	1
2159	Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. 2005 , 1, 19-22	11
2158	Hormonotherapy of advanced prostate cancer. 2005 , 16 Suppl 4, iv80-84	12
2157	Exisulind in the treatment of prostate cancer. 2005 , 5, 957-62	12

2156	Docetaxel in the management of ovarian cancer. 2005 , 5, 203-14	6
2155	Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. 2005 , 5, 419-27	26
2154	Docetaxel for the treatment of prostate cancer. 2005 , 1, 307-14	11
2153	Chemotherapy for advanced prostate cancer. <i>New England Journal of Medicine</i> , 2005 , 352, 200-1; author reply 200-1	59.2 1
2152	Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. 2005 , 9, 561-70	35
2151	Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. 2005 , 11, 4037-43	173
2150	New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. 2005 , 5, 53-62	5
2149	Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. 2005 , 65, 9021-8	157
2148	Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. 2005 , 23, 4975-9	93
2147	Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. 2005 , 23, 8724-9	142
2146	Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. 2005 , 23, 6556-60	81
2145	Symptoms in cancer patients and an unusual tumor: Case 2. Docetaxel-related ischemic colitis. 2005 , 23, 9424-5	11
2144	Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. 2005 , 23, 6992-8	165
2143	Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. 2005 , 11, 8680-5	64
2142	In Reply:. 2005 , 23, 8125-8126	1
2141	Patient online self-reporting of toxicity symptoms during chemotherapy. 2005 , 23, 3552-61	222
2140	Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. 2005 , 23, 2789-96	26
2139	Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. 2005 , 23, 4424-9	140

2138	Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. 2005 , 65, 11667-75	173
2137	A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. 2005 , 11, 3854-61	156
2136	Prostate cancer clinical trial end points: "RECIST"ing a step backwards. 2005 , 11, 5223-32	116
2135	PSA kinetics and risk of death from prostate cancer: in search of the Holy Grail of surrogate end points. 2005 , 294, 493-4	2
2134	Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. 2005 , 23, 3352-7	23
2133	Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. 2005 , 294, 433-9	979
2132	Drug insight: Use of docetaxel in prostate and urothelial cancers. 2005 , 2, 92-100; quiz 1 p following 112	44
2131	Present status and perspectives in the treatment of hormone-refractory prostate cancer. 2005 , 69, 273-82	19
2130	Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemma. 2005 , 28, 361-6	11
2129	Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. 2005 , 28, 573-8	8
2128	Managing metastatic prostate cancer. 2005 , 66, 618-22	
2127	A phase II study of perifosine in androgen independent prostate cancer. 2005 , 4, 1133-7	88
2126	C?ncer de pr?stata avanzado. 2005 , 9, 1772-1780	
2125	Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice. 2005 , 59 Suppl 2, S306-10	24
2124	Nouvelles de lâindustrie pharmaceutique La Presse M?dicale - Volume 34, Issue 8. 2005 , 34, 618	
2123	Docetaxel for treatment of solid tumours: a systematic review of clinical data. 2005 , 6, 229-39	217
2122	Radioisotopes for metastatic bone pain. 2005 , 6, 353-4	4
2121	[Update of the treatment of advanced prostate cancer and management of its complications]. 2005 , 125, 671-7	0

2120	Treatments for hormonal refractory prostate cancer. 2005 , 3, 339-343	
2119	74 INVITED Molecular pathology in prostate cancer. 2005 , 3, 20-21	
2118	76 INVITED The evolving role of chemotherapy in prostate cancer. 2005 , 3, 21	
2117	77 INVITED Targeted therapy in androgen-independent prostate cancer. 2005 , 3, 21-22	
2116	Progress in oncology and progress for Acta Oncologica. 2005 , 44, 9-10	0
2115	Which drug combination for hormone-refractory prostate cancer?. 2005 , 6, 667-70	1
2114	Management of advanced prostate cancer after first-line chemotherapy. 2005 , 23, 8247-52	79
2113	Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. 2005 , 23, 8253-61	826
2112	Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. 2005 , 8, 75-83	100
2111	Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy. 2005 , 41, 502-7	18
2110	Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?. 2005 , 41, 941-53	44
2109	Docetaxel administration schedule: from fever to tears? A review of randomised studies. 2005 , 41, 1117-26	77
2108	Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen. 2005 , 65, 947-52	7
2107	Introduction. 2005 , 65, 1	
2106	Hormone-refractory prostate cancer: Issues, approaches, and recommendations. 2005 , 65, 1-2	0
2105	National cooperative group trials. 2005 , 65, 23-9; discussion 29	50
2104	Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials. 2005 , 65, 18-22; discussion 22	10
2103	The current role of chemotherapy in metastatic hormone-refractory prostate cancer. 2005 , 65, 3-7; discussion 7-8	69

2102	An interdisciplinary approach to treating prostate cancer. 2005 , 65, 13-8	11
2101	The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. 2005 , 65, 2-7	36
2100	Future directions in the treatment of androgen-independent prostate cancer. 2005 , 65, 8-12	53
2099	A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. 2005 , 4, 1689-98	92
2098	Docetaxel in hormone-refractory metastatic prostate cancer. 2005 , 65, 2287-94; discussion 2295-7	13
2097	Genetic alterations in prostate cancer. 2005 , 3, 220-9	1
2096	Prostate-specific antigen endpoints in hormone-refractory prostate cancer. 2005 , 4, 5-6	
2095	Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. 2005 , 4, 61-4	10
2094	Second-line chemotherapy for prostate cancer: patient characteristics and survival. 2005 , 4, 86-90	26
2093	Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. 2005 , 4, 91-9	11
2092	Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer. 2005 , 4, 113-7	2
2091	A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. 2005 , 4, 138-41	49
2090	Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. 2005 , 4, 212-4	16
2089	[Prostate cancer chemotherapy, myth or reality?]. 2005 , 29, 723-4	
2088	Medical and surgical palliative care of patients with urological malignancies. 2005 , 174, 1177-82	37
2087	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer. 2005 , 16 Suppl 1, i34-6	24
2086	The Battle Against Hormone-Refractory Prostate Cancer. 2006 , 4, 7-9	
2085	Immunotherapy for Prostate Cancer. 2006 , 5, 331-339	

2084	5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA). 2006 , 5, 155-162	18
2083	Management Strategies for Hormone-Refractory Prostate Cancer. 2006 , 5, 163-169	
2082	Nanoparticle-aptamer bioconjugates for targeted antineoplastic drug delivery. 2006 , 4, 123-130	3
2081	Molecular Chaperones in Health and Disease. 2006 ,	2
2080	Chemotherapy for advanced prostate cancer: docetaxel and beyond. 2006 , 20, 935-46, x	3
2079	The case for early chemotherapy for the treatment of metastatic disease. 2006 , 176, S72-5	15
2078	Epothilones in the treatment of cancer. 2006 , 15, 691-702	62
2077	Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review. 2006 , 24, 517-20	2
2076	Hsp90 inhibitors in the clinic. 2006 , 331-58	77
2075	Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. 2006 , 7, 425-30	85
2074	[Difficult clinical cases in prostate cancer: multidisciplinary staff, the rational principles of adjuvant therapy and other therapeutic options]. 2006 , 40 Suppl 2, S35-41	
2073	[Synthesis of the multidisciplinary consensus meeting on prostatic cancer]. 2006 , 40 Suppl 2, S42-3	
2072	Introduction. 2006 , 5, 537-538	
2071	The Treatment Continuum in the Management of Prostate Cancer Patients: What's New?. 2006 , 5, 539-542	4
2070	Treatment of Prostate Cancer in the 21st Century—Future Directions. 2006 , 5, 824-829	0
2069	New Hope for Patients with Metastatic Hormone-Refractory Prostate Cancer. 2006 , 5, 817-823	5
2068	Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. 2006 , 175, 1347-52	28
2067	Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. 2006 , 175, 1684-90; discussion 1690	20

2066	Changing perspectives of the role of chemotherapy in advanced prostate cancer. 2006 , 33, 227-36, vii	2
2065	Management of high risk metastatic prostate cancer: the case for novel therapies. 2006 , 176, S76-80; discussion S81-2	6
2064	Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024. 2006 , 176, 548-53; discussion 553	8
2063	The case for adjuvant therapy for prostate cancer. 2006 , 176, S30-3	2
2062	The case for systemic therapy alone for prostate cancer. 2006 , 176, S42-6	1
2061	[Hormone-refractory prostate cancer. Modifications of the therapeutic strategies since chemotherapy proved its usefulness]. 2006 , 30, 123-33	3
2060	Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. 2006 , 176, S11-5	28
2059	Clinical pharmacokinetics of docetaxel : recent developments. 2006 , 45, 235-52	125
2058	Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate-specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. 2006 , 4, 287-92	6
2057	A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. 2006 , 5, 131-7	21
2056	Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. 2006 , 5, 144-9	12
2055	Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer. 2006 , 5, 155-61	11
2054	Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer. 2006 , 5, 212-8	4
2053	A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. 2006 , 4, 1	126
2052	Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. 2006 , 24, 3089-94	871
2051	Secondary hormonal therapy for advanced prostate cancer. 2006 , 175, 27-34	125
2050	Satraplatin: an orally available platinum analog for the treatment of cancer. 2006 , 6, 973-82	69
2049	Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. 2006 , 28, 1485-508	62

2048	Hormone refractory prostate cancer: Management and advances. 2006 , 32, 90-100	24
2047	Insight into the treatment of cancer in older patients: developments in the last decade. 2006 , 32, 277-88	19
2046	Novel Therapies in Advanced Prostate Cancer. 2006 , 4, 161-170	
2045	A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. 2006 , 42, 200-4	20
2044	Update on tubulin-binding agents. 2006 , 54, 72-84	117
2043	Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. 2006 , 67, 354-9	20
2042	Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. 2006 , 67, 1235-40	46
2041	Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. 2006 , 68, 110-5	29
2040	Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. 2006 , 68, 565-9	30
2039	Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. 2006 , 24, 434-41	30
2038	Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. 2006 , 24, 419-24	118
2037	Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. 2006 , 24, 396-402	45
2036	Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model. 2006 , 24, 141-51	14
2035	The use of thalidomide in androgen-independent prostate cancer. 2006 , 24, 246-9	12
2034	Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. 2006 , 24, 250-3	32
2033	Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. 2006 , 24, 254-9	27
2032	Hormone Refractory Prostate Cancer (Hrpc): Present and Future Approaches of Therapy. 2006 , 19, 205873920601900	
2031	Novel agents and targets in managing patients with metastatic prostate cancer. 2006 , 13, 194-8	9

2030 Even more cost savings?. **2006**, 2, 202

2029 Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs. **2006**, 2, 57-66 3

2028 . **2006**,

2027 The war on cancer: a report from the front lines. **2006**, 19, 323-34 1

2026 Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. **2006**, 2, 249-58 21

2025 Chemotherapy for hormone-refractory prostate cancer. **2006**, CD005247 46

2024 Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis. **2006**, 15, 519

2023 New approaches in hormone refractory prostate cancer. **2006**, 29, 196-201 11

2022 Androgen receptor as a therapeutic target for androgen independent prostate cancer. **2006**, 13, 166-70 33

2021 Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. **2006**, 12, 299-304 9

2020 Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence. **2006**, 1, 219-226

2019 Immunologic targeting: how to channel a minimal response for maximal outcome. **2006**, 16, 179-85 3

2018 Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. **2006**, 29, 395-8 19

2017 New drugs in prostate cancer. **2006**, 16, 138-45 19

2016 Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. **2006**, 17, 993-6 31

2015 Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine. **2006**, 17, 807-13 4

2014 A phase II study of higher dose docetaxel in androgen-independent prostate cancer. **2006**, 29, 389-94 4

2013 Pharmacotherapy in the Management of Prostate Cancer. 159-175

2012	Numerical and functional assessment of blood dendritic cells in prostate cancer patients. 2006 , 66, 180-92	23
2011	Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer. 2006 , 66, 1487-97	13
2010	Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates. 2006 , 66, 1753-67	12
2009	Side-effects of treatments for locally advanced prostate cancer. 2006 , 97, 22-8	21
2008	Anti-emetic therapy: updating urological cancer-care providers. 2006 , 97, 673-5	1
2007	Chemotherapy for high-risk localized prostate cancer. 2006 , 97, 679-83	4
2006	Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. 2006 , 97, 1300-8	54
2005	Interfering with cell-survival signalling as a treatment strategy for prostate cancer. 2006 , 97, 1149-53	8
2004	Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. 2006 , 98, 445-51	64
2003	A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. 2006 , 98, 580-5	13
2002	Improving outcomes in early prostate cancer: Part I--adjuvant treatment. 2006 , 98, 725-30	6
2001	Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. 2006 , 97, 235-41	37
2000	Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. 2006 , 94, 1592-8	68
1999	A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. 2006 , 95, 457-62	18
1998	The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. 2006 , 25, 2082-93	46
1997	Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. 2006 , 25, 6113-22	90
1996	Predictors of mortality after prostate-specific antigen failure. 2006 , 65, 656-60	30
1995	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. 2006 , 103, 6315-20	1448

1994	Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. 2006 , 15, 1297-306	54
1993	A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. 2006 , 24, 125-34	29
1992	Therapie des hormonresistenten Prostatakarzinoms mit Docetaxel. 2006 , 12, 798-802	
1991	Vakzinetherapie des Prostatakarzinoms mit autologen dendritischen Zellen zeigt Überlebensvorteil. 2006 , 12, 1150-1152	
1990	Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells. 2006 , 11, 1205-14	69
1989	What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?. 2006 , 132 Suppl 1, S27-35	7
1988	Possibility of recovery of estrogen sensitivity following high-dose glucocorticoid therapy in a patient with hormone-refractory prostate cancer. 2006 , 11, 326-8	
1987	Qualité de vie et sujets âgés en cancérologie. 2006 , 8, 460-464	
1986	A phase 2 study of high-activity ¹⁸⁶ Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. 2006 , 33, 1055-61	21
1985	Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. 2006 , 55, 1524-33	94
1984	Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. 2006 , 57, 46-51	15
1983	A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. 2006 , 58, 809-15	14
1982	[Therapeutic options for hormone-refractory prostate cancer]. 2006 , 45, 580, 582-5	
1981	[Future of chemotherapy]. 2006 , 45, 567-71	0
1980	[Off-label use in oncology: an inexhaustible topic?!]. 2006 , 45, 1410, 1412-4	2
1979	Cytotoxic chemotherapy for prostate cancer: Who and when?. 2006 , 7, 370-7	3
1978	Targeted approaches for the management of metastatic prostate cancer. 2006 , 8, 206-12	3
1977	The role of primary chemotherapy for prostate cancer: Has the time come?. 2006 , 4, 157-162	

1976	The role of primary chemotherapy for prostate cancer: has the time come?. 2006 , 7, 233-8	
1975	Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer. 2006 , 49, 666-74	50
1974	Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?. 2006 , 49, 781-9	17
1973	Re: Secondary Hormonal Therapy for Advanced Prostate Cancer. 2006 , 49, 925-926	1
1972	Management of the spectrum of hormone refractory prostate cancer. 2006 , 50, 428-38; discussion 438-9	39
1971	Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. 2006 , 71, 751-60	33
1970	Highlights from The 2006 American Society of Clinical Oncology Prostate Cancer Symposium San Francisco, CA; February 24-26, 2006. 2006 , 4, 240-5	
1969	Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA; June 2-6, 2006. 2006 , 5, 18-22	
1968	Oncology. 2006 , 34, 557-560	1
1967	Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. 2006 , 6, 112	39
1966	Docetaxel-associated epiphora. 2006 , 26, 853-67	40
1965	Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. 2006 , 4, 249-56	23
1964	A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer. 2006 , 4, 281-6	13
1963	A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. 2006 , 106, 58-62	28
1962	Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. 2006 , 106, 63-7	30
1961	First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?. 2006 , 106, 1041-6	63
1960	Critical analysis of prostate-specific antigen doubling time calculation methodology. 2006 , 106, 1047-53	45
1959	Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. 2006 , 106, 1715-21	10

1958	Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. 2006 , 106, 1917-24	34
1957	Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. 2006 , 106, 2459-65	16
1956	Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. 2006 , 106, 2143-7	14
1955	Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. 2006 , 106, 2617-23	4
1954	A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. 2006 , 107, 266-74	52
1953	Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. 2006 , 107, 514-20	23
1952	Thapsigargin resistance in human prostate cancer cells. 2006 , 107, 649-59	9
1951	Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. 2006 , 107, 521-9	97
1950	Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. 2006 , 107, 864-73	81
1949	Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. 2006 , 107, 738-45	31
1948	Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. 2006 , 107, 975-81	38
1947	Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. 2006 , 107, 2597-603	32
1946	Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. 2006 , 119, 2428-34	70
1945	Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. 2006 , 12, 169-74	31
1944	Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells. 2006 , 5, 1342-51	48
1943	Mechanisms underlying the development of androgen-independent prostate cancer. 2006 , 12, 1665-71	338
1942	Geriatrische Urologie - Tumorerkrankungen. 2006 , 27, 37-43	
1941	Are prostate cancer clinical trial enrollment criteria and endpoints appropriate?. 2006 , 3, 74-5	2

1940	Anthracyclines as effective anticancer drugs. 2006 , 1, 549-68	40
1939	Systemic treatment for prostate cancer. 2006 , 17 Suppl 10, x211-3	1
1938	Hormone-refractory prostate cancer: a shifting paradigm in treatment. 2006 , 10, 233-40	8
1937	Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. 2006 , 98, 516-21	229
1936	Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. 2006 , 24, 2828-35	73
1935	The changing pattern of management for hormone-refractory, metastatic prostate cancer. 2006 , 9, 221-9	14
1934	Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. 2006 , 12, 6116-24	127
1933	Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. 2006 , 24, 3075-80	103
1932	Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. 2006 , 12, 6153-60	75
1931	Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. 2006 , 24, 1982-9	65
1930	Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. 2006 , 5, 1216-26	26
1929	Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer. 2006 , 9, 92-8	10
1928	Therapeutic vaccines for prostate cancer. 2006 , 11, 451-62	32
1927	Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. 2006 , 12, 6094-9	58
1926	Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. 2006 , 12, 5578-86	136
1925	Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. 2006 , 24, 5408-13	22
1924	Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments. 2006 , 7, 1685-99	4
1923	Sipuleucel-T (APC8015) for prostate cancer. 2006 , 6, 1163-7	43

1922	A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. 2006 , 12, 1260-9	251
1921	Prostate Cancer. 2006 ,	
1920	Evolving treatment paradigms for locally advanced and metastatic prostate cancer. 2006 , 6, 1639-51	3
1919	The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. 2006 , 15, 507-17	21
1918	Management of prostate cancer. Part 3: metastatic disease. 2006 , 6, 813-21	2
1917	A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. 2006 , 14, 107-17	187
1916	Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. 2006 , 95, 767-74	63
1915	Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. 2006 , 3, 658-67	50
1914	Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study. 2006 , 3, 536-7	
1913	Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. 2006 , 15, 795-804	9
1912	Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. 2006 , 66, 4816-25	114
1911	A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. 2006 , 12, 1556-63	56
1910	New molecular targets in advanced prostate cancer. 2006 , 6, 993-1002	8
1909	Prostate Cancer. 2007 ,	4
1908	Complications arising in the final year of life in men dying from advanced prostate cancer. 2007 , 10, 705-11	34
1907	Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. 2007 , 99, 1613-22	51
1906	Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. 2007 , 13, 1208-15	58
1905	Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. 2007 , 67, 5117-25	147

1904	Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. 2007 , 25, 669-74	254
1903	Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). 2007 , 7, 1275-80	40
1902	The role of stress proteins in prostate cancer. 2007 , 8, 252-61	33
1901	Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. 2007 , 46, 664-8	42
1900	Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. 2007 , 18, 1828-33	46
1899	Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. 2007 , 321, 1109-17	18
1898	Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. 2007 , 13, 5825-33	54
1897	Complications of Urologic Surgery and Practice. 2007 ,	2
1896	A bifunctional colchicinoid that binds to the androgen receptor. 2007 , 6, 2328-36	11
1895	Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2007 , 18 Suppl 2, ii36-7	5
1894	Epothilones in prostate cancer: review of clinical experience. 2007 , 18 Suppl 5, v22-7	11
1893	Prostate cancer: a chronic illness. 2007 , 11, 857-61	7
1892	Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. 2007 , 28, 1463-70	103
1891	In Reply. 2007 , 25, 5674-5674	
1890	Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation. 2007 , 10, 396-7	7
1889	Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy. 2007 , 10, 119-26	6
1888	A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. 2007 , 13, 6396-403	288
1887	Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. 2007 , 6, 313-7	28

1886	Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. 2007 , 6, 1360-7	24
1885	Cytokeratin markers come of age. 2007 , 28, 189-95	70
1884	Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. 2007 , 4 Suppl 1, S3-13	9
1883	Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. 2007 , 4, 82-94	9
1882	Positron emission tomography imaging as a cancer biomarker. 2007 , 7, 659-72	16
1881	Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. 2007 , 18, 1064-70	43
1880	Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. 2007 , 25, 3965-70	221
1879	Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. 2007 , 13, 2199-206	113
1878	Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. 2007 , 25, 1596-605	435
1877	Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer. 2007 , 13, 1847-56	69
1876	Do general dimensions of quality of life add clinical value to symptom data?. 2007 , 31-8	11
1875	Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. 2007 , 25, 675-81	84
1874	Cancer Stem Cells. 2007 ,	2
1873	Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. 2007 , 6, 742-51	35
1872	Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. 2007 , 67, 9417-24	272
1871	Prostate cancer stem cells: a target for new therapies. 2006 , 155-79	28
1870	Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone. 2007 , 37, 603-8	17
1869	The role of Src in prostate cancer. 2007 , 18, 1765-73	144

1868	Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. 2007 , 13, 3883-91	189
1867	MUC1 is a promising therapeutic target for prostate cancer therapy. 2007 , 7, 259-71	38
1866	Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer. 2007 , 37, 424-8	22
1865	Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. 2007 , 67, 5318-27	168
1864	Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. 2007 , 79, 307-11	9
1863	Somatostatin effects on the proteome of the LNCaP cell-line. 2007 , 30, 1173	3
1862	An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. 2007 , 30, 355-60	19
1861	Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. 2007 ,	1
1860	Bone metastases in prostate cancer: a targeted approach. 2007 , 19, 254-8	11
1859	Novel targets and approaches in advanced prostate cancer. 2007 , 17, 182-7	22
1858	Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. 2007 , 13, 125-9	12
1857	Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature. 2007 , 14, 310-3	3
1856	Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. 2007 , 30, 428-31	42
1855	Neoadjuvant therapy and prostate cancer: what a urologist should know. 2007 , 17, 188-93	4
1854	Management of hormone refractory prostate cancer. 2007 , 1, 187-91	3
1853	Prostate cancer immunotherapy. 2007 , 17, 175-81	20
1852	Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer. 2007 , 30, 234-8	5
1851	Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer. 2007 , 18, 233-5	3

1850	The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 brachytherapy. 2007 , 30, 597-600	4
1849	The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer. 2007 , 2, 203-11	13
1848	Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!. 2007 , 25, 5673-4; author reply 5674	10
1847	Prostate Cancer: A Practical Approach to Current Management of Recurrent Disease. 2007 , 82, 243-249	45
1846	Prostate cancer presentation, diagnosis and treatment: what does the literature say?. 2007 , 1, 6-17	4
1845	The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics. 2007 , 6, 1307-13	30
1844	Tubulin Targeting Agents. 2007 , 2, 1-18	19
1843	Antiandrogen therapy in prostate cancer. 2007 , 2, 119-131	1
1842	Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. 2007 , 69, 142-6	18
1841	Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. 2007 , 69, 347-51	12
1840	Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction. 2007 , 69, 795-9	13
1839	Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel. 2007 , 70, 396-401	18
1838	Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response. 2007 , 70, 320-3	2
1837	Neoadjuvant therapy before radical prostatectomy: where have we been? Where are we going?. 2007 , 25, 11-8	18
1836	Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial. 2007 , 25, 207-13	2
1835	Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy. 2007 , 25, 284-90	14
1834	Fuzzy thinking on biomarkers. 2007 , 25, 97-100	1
1833	Vaccine therapy for prostate cancer. 2007 , 25, 451-9	8

1832	Therapeutic options for hormone-refractory prostate cancer in 2007. 2007 , 25, 413-9	52
1831	Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: A multi-institutional pilot study. 2007 , 25, 528-529	
1830	Prostate-specific antigen velocity, and prostate cancer Gleason grade and stage. 2007 , 25, 529-530	
1829	GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. 2007 , 7, 1893-902	41
1828	[Hormone-refractory prostate cancer]. 2007 , 41, 47-55	5
1827	Radionuclide Treatment in Metastasized Prostate Cancer. 2007 , 5, 113-125	3
1826	Prostate cancer: Re-focusing on androgen receptor signaling. 2007 , 39, 1562-8	35
1825	Cellular immunotherapies for prostate cancer. 2007 , 61, 315-22	9
1824	Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. 2007 , 247, 122-9	35
1823	Advanced Prostate Cancer: Hormones and Beyond. 2007 , 6, 354-364	3
1822	What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006. 2007 , 6, 404-412	1
1821	Advances in Oncological Urology—the Oncoforum Programme. 2007 , 6, 821-828	2
1820	Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. 2007 , 8, 587-94	397
1819	Radium-223 for men with hormone-refractory prostate cancer and bone metastases. 2007 , 8, 564-5	5
1818	Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. 2007 , 8, 994-1000	86
1817	Estramustine in prostate cancer: new look at an old drug. 2007 , 8, 959-61	2
1816	Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. 2007 , 25, 5106-12	310
1815	Treatment options for the advanced asymptomatic prostate cancer patient: an active immunotherapy approach. 2007 , 4, 447-452	1

1814 Căcer de prŃstata hormonoresistentă. **2007**, 39, 1-7

1813 Microtubule Protocols. **2007**, 3

1812 Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. **2007**, 8, R255 65

1811 Advances in prostate cancer immunotherapies. **2007**, 24, 197-221 12

1810 Metastasis of Prostate Cancer. **2007**, 2

1809 [Promising new treatment options for metastatic androgen-independent prostate cancer]. **2007**, 31, 680-5 3

1808 Fractionation of high molecular weight tannins in grape seed extract and identification of procyanidin B2-3,3'-di-O-gallate as a major active constituent causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells. **2007**, 28, 1478-84 64

1807 Pharmacoeconomics of available treatment options for metastatic prostate cancer. **2007**, 25, 309-27 6

1806 Genomic signatures associated with the development, progression, and outcome of prostate cancer. **2007**, 11, 345-54 7

1805 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy. **2007**, 7, 1463-9 8

1804 A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. **2007**, 25, 435-44 9

1803 Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades. **2007**, 25, 400-16 22

1802 Enhanced antitumor effects by the coculture of allotumor RNA-pulsed dendritic cells with autologous cytokine-induced killer cells on hormone-refractory prostate cancer. **2007**, 25, 527-34 1

1801 Bone directed therapies for prostate cancer. **2007**, 178, S42-8 9

1800 [Active immunotherapy of prostate cancer with a focus on dendritic cells]. **2007**, 31, 668-79 2

1799 A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer. **2007**, 177, 2141-5; discussion 2145 6

1798 [Natural history of metastatic prostate cancer treated with androgen deprivation therapy and secondary hormonal therapy efficiency]. **2007**, 31, 714-8

1797 Taxane refractory prostate cancer. **2007**, 178, S36-41 22

1796	International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature. 2007 , 25, 1832-43	180
1795	A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. 2007 , 9, 1003-11	92
1794	Clinical safety of a viral vector based prostate cancer vaccine strategy. 2007 , 178, 1515-20	109
1793	Prostate cancer: a practical approach to current management of recurrent disease. 2007 , 82, 243-9	51
1792	Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. 2007 , 177, 1777-81	38
1791	[Current treatment in high risk and locally advanced prostate cancer]. 2007 , 31, 445-51	2
1790	[Prostatic cancers]. 2007 , 17, 1159-230	10
1789	Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. 2007 , 178, 844-8; discussion 848	55
1788	Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions. 2007 , 178, S30-5	5
1787	Current immunotherapeutic strategies in prostate cancer. 2007 , 16, 861-71, x	1
1786	Guideline for the management of clinically localized prostate cancer: 2007 update. 2007 , 177, 2106-31	862
1785	Editorial Comment. 2007 , 177, 2140-2140	
1784	Novel expressed sequences identified in a model of androgen independent prostate cancer. 2007 , 8, 32	3
1783	Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation. 2007 , 67, 859-69	13
1782	Hormone-refractory prostate cancer: where are we going?. 2007 , 67, 1109-24	13
1781	Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. 2007 , 5, 318-22	7
1780	Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. 2007 , 5, 344-6	45
1779	Exogenous mycoplasmal p37 protein alters gene expression, growth and morphology of prostate cancer cells. 2007 , 118, 204-13	31

- 1778 Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. **2007**, 25, 32-7 40
- 1777 A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. **2007**, 178, 2378-83; discussion 2383-4 35
- 1776 Distilling the Past âEnvisioning the Future. **2008**, 355-397
- 1775 Strategies for the Implementation of Chemotherapy and Radiotherapy. **2008**, 309-335
- 1774 Biology and clinical management of prostate cancer bone metastasis. **2007**, 12, 3273-86 30
- 1773 Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. **2007**, 12, 4957-71 118
- 1772 A Pilot Study of a Day One and Eight Every Three Weeks Administration of Docetaxel in Metastatic Cancer Patients. **2007**, 93, 145-149
- 1771 Estramustine Phosphate Based Chemotherapy for Hormone Refractory Prostate Cancer. **2007**, 48, 684 4
- 1770 Cancer. **2007**, 533-545
- 1769 Nuclear and Cytoplasmic Expression of ErbB-4 in Prostate Cancer. **2007**, 22, 181-185 2
- 1768 Multidisciplinary Management of Genitourinary Malignancies. **2007**,
- 1767 Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. **2007**, 120, 2028-33 45
- 1766 Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. **2007**, 120, 1603-9 45
- 1765 Immunotherapy with dendritic cells for prostate cancer. **2007**, 121, 467-73 31
- 1764 Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?. **2007**, 109, 477-86 54
- 1763 Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. **2007**, 109, 1290-5 21
- 1762 Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. **2007**, 110, 56-61 44
- 1761 Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. **2007**, 110, 556-63 156

1760	Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. 2007 , 110, 1248-54	49
1759	Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. 2007 , 110, 996-1002	16
1758	A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. 2007 , 110, 1959-66	252
1757	Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. 2007 , 110, 2628-39	16
1756	Intermittent chemotherapy for metastatic hormone refractory prostate cancer. 2007 , 61, 243-54	22
1755	Prostate cancer and race. 2007 , 31, 211-25	28
1754	Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome. 2007 , 68, 699-706	16
1753	Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells—a pilot study. 2007 , 67, 500-8	41
1752	ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. 2007 , 67, 871-80	14
1751	IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats. 2007 , 67, 701-13	11
1750	Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. 2007 , 67, 900-6	40
1749	The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. 2007 , 67, 955-67	106
1748	A population study of neutering status as a risk factor for canine prostate cancer. 2007 , 67, 1174-81	112
1747	Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. 2007 , 67, 1081-90	44
1746	Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. 2007 , 67, 1121-31	81
1745	Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria. 2007 , 67, 1543-9	10
1744	Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. 2007 , 67, 1475-85	21
1743	An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. 2007 , 14, 652-60	19

1742	Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. 2007 , 97, 1206-10	17
1741	A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. 2007 , 97, 1480-5	89
1740	Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer. 2007 , 97, 1613-7	5
1739	Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer. 2007 , 51, 584-8	13
1738	The medical management of prostate cancer: a multidisciplinary team approach. 2007 , 99, 22-7	26
1737	Chemotherapy for older patients with prostate cancer. 2007 , 99, 269-73	18
1736	Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. 2007 , 99, 525-8	6
1735	Liver metastases in prostate carcinoma: clinical characteristics and outcome. 2007 , 99, 807-11	48
1734	Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. 2007 , 99, 1047-55	41
1733	Editorial. Prostate cancer update. 2007 , 100 Suppl 2, 1	2
1732	Hormone-refractory prostate cancer: what have we learned?. 2007 , 100 Suppl 2, 56-9	3
1731	Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis. 2007 , 100 Suppl 2, 60-2	8
1730	Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. 2007 , 100, 775-9	24
1729	Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. 2007 , 100, 533-5	3
1728	Intermittent chemotherapy in metastatic androgen-independent prostate cancer. 2007 , 100, 490-2	7
1727	Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer. 2007 , 100, 770-4	11
1726	A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. 2007 , 100, 765-9	54
1725	Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. 2008 , 101, 440-3	57

1724	Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. 2008 , 99, 81-6	159
1723	Web-based health survey systems in outcome assessment and management of pain. 2007 , 8 Suppl 3, S189-98	11
1722	A long and winding road: the role of chemotherapy for hormone-refractory prostate cancer. 2007 , 61, 1964-5	
1721	Chemotherapy for the treatment of hormone-refractory prostate cancer. 2007 , 61, 2064-70	27
1720	Experience with docetaxel in hormone-refractory prostate cancer (HRPC) at three Australian cancer centers: A retrospective study. 2007 , 3, 156-162	
1719	Phase II trial of anti-idiotypic p53 peptides (Pentrys) plus granulocyte-macrophage colony-stimulating factor in patients with hormone-refractory prostate cancer. 2007 , 3, 148-155	
1718	Immediate versus delayed chemotherapy in patients with asymptomatic incurable metastatic cancer. 2007 , 3, 071011204603001-???	
1717	Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. 2007 , 28, 1466-75	53
1716	Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. 2007 , 5, 278-83	35
1715	Chemotherapy in prostate cancer: an update. 2007 , 5, 304-5	1
1714	A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. 2007 , 5, 323-8	20
1713	Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer. 2007 , 5, 329-33	4
1712	Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. 2007 , 5, 347-50	10
1711	Survival analyses overview in hormone-refractory prostate cancer clinical trials in the prostate-specific antigen era. 2007 , 5, 420-1	
1710	Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. 2007 , 5, 457-9	9
1709	A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. 2007 , 7, 142	60
1708	Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells. 2007 , 1773, 1087-94	30
1707	Current indications for chemotherapy in prostate cancer patients. 2007 , 51, 17-26	54

1706	Advanced prostate cancer: at last a role for medical oncologists. 2007 , 51, 4-5	2
1705	Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. 2007 , 51, 27-33	18
1704	Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. 2007 , 51, 1252-8	23
1703	Docetaxel and beyond. 2007 , 51, 1159-61	2
1702	Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. 2007 , 52, 1691-8	38
1701	Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. 2007 , 52, 1698-9	
1700	Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 2007 , 52, 1020-7	13
1699	New treatment strategies in the management of hormone refractory prostate cancer (HRPC): only chemotherapy?. 2007 , 52, 945-7	7
1698	Highlights from: The 2007 Prostate Cancer Symposium, February 22-24, 2007; Orlando, FL. 2007 , 5, 249-55	3
1697	Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL. 2007 , 5, 362-370	
1696	Advances in the treatment of prostate cancer. 2007 , 58, 205-20	27
1695	Chemotherapie bij hormoonrefractair prostaatacarcinoom. 2007 , 50, 361-362	
1694	[Differential therapy of prostate cancer]. 2007 , 48, 1382-7	
1693	[Palliative and supportive treatment options in patients with advanced prostate cancer]. 2007 , 46, 30-5	1
1692	[Stress proteins in prostate cancer. Challenge and promise]. 2007 , 46, 516-20	1
1691	[Lethal course after chemotherapy with docetaxel. Acute liver failure with accompanying erythema multiforme major]. 2007 , 46, 1425-7	6
1690	[Optimizing treatment of advanced urologic malignancies]. 2007 , 46, 1278-84	0
1689	Clinical benefit of bone-targeted radiometabolic therapy with ¹⁵³ Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. 2007 , 34, 1023-30	47

1688	Vaccination therapy in prostate cancer. 2007 , 56, 429-45	18
1687	Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. 2008 , 61, 53-61	2
1686	Preclinical antitumor activity of the oral platinum analog satraplatin. 2007 , 60, 589-600	46
1685	Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. 2007 , 16, 571-5	52
1684	Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. 2007 , 25, 565-70	46
1683	The central role of osteoblasts in the metastasis of prostate cancer. 2006 , 25, 601-9	29
1682	Quelle valuation gfontologique faut-il utiliser pour les essais multicentriques?. 2007 , 9, 186-191	1
1681	Cancer avancde la prostate et maladie osseuse mfastatique. 2007 , 9, 564-572	
1680	[The hormone refractory prostate cancer - a challenge for the internal specialist]. 2007 , 157, 145-8	
1679	Urologische Aspekte in der Palliativmedizin. 2007 , 13, 602-608	
1678	Symptomkontrollierende Effekte der Chemotherapie. 2007 , 13, 619-624	1
1677	Metastasiertes hormonrefrakties Prostatakarzinom. 2007 , 13, 726-731	1
1676	Prostatakarzinom. 2007 , 13, 840-846	
1675	Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. 2008 , 134, 51-7	43
1674	Clinical trials in metastatic hormone-refractory prostate cancer: improving docetaxel therapy by targeting bone-related growth factors. 2007 , 9, 211-2	1
1673	Bone metabolism and new targets for intervention. 2007 , 5, 55-60	
1672	Bone metabolism and new targets for intervention. 2007 , 8, 233-8	2
1671	The spectrum of prostate cancer care: from curative intent to palliation. 2007 , 8, 245-52	4

1670	Therapeutic options in advanced prostate cancer: present and future. 2007 , 8, 53-9	18
1669	Current perspectives in the treatment of advanced prostate cancer. 2007 , 24, 273-86	11
1668	Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients. 2007 , 9, 323-8	3
1667	Targeted therapy in hormone refractory prostate cancer. 2007 , 2, 235-240	
1666	Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. 2007 , 61, 176-85	35
1665	Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology program. 2008 , 66, 163-70	53
1664	Prostate cancer. Multidisciplinary approach: a key to success. 2008 , 68 Suppl 1, S32-6	12
1663	Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. 2008 , 40, 97-104	29
1662	Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). 2008 , 26, 75-9	15
1661	Le traitement des cancers de la prostate hormonorésistants. 2008 , 14, 29-36	
1660	Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases. 2008 , 35, 1394-1395	2
1659	A novel murine model of allogeneic vaccination against prostate cancer. 2008 , 57, 453-65	9
1658	Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. 2008 , 62, 373-7	8
1657	Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. 2008 , 62, 417-26	22
1656	Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. 2008 , 62, 551-7	19
1655	Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. 2008 , 26, 509-16	20
1654	[Value of targeted therapy for prostate cancer]. 2008 , 47, 1315-9	
1653	[Somatostatin analogs for the treatment of advanced, hormone-refractory prostate cancer: a possibility for secondary hormonal ablation?]. 2008 , 47, 1334-8	1

1652	[Clinical network structures in uro-oncology. A model for the future?]. 2008 , 47, 1128-32	1
1651	[Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer]. 2008 , 47, 1218-23	0
1650	A new era in prostate cancer therapy: new targets and novel therapeutics. 2008 , 3, 31-39	
1649	Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. 2008 , 9, 191-203	44
1648	The spectrum of prostate cancer care: From curative intent to palliation. 2008 , 6, 56-63	
1647	Systems biology: a therapeutic target for tumor therapy. 2008 , 1, 159-70	52
1646	Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma. 2008 , 10, 372-4	1
1645	Prostatakarzinom. 2008 , 14, 1087-1102	
1644	Current topics and perspectives relating to hormone therapy for prostate cancer. 2008 , 13, 401-10	22
1643	Cancer de la prostate m̄tastatique: quoi de neuf depuis le docetaxel ?. 2008 , 10, 648-652	
1642	[Chemotherapy for prostate cancer]. 2008 , 120, 440-9	2
1641	Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts. 2008 , 134, 833-9	16
1640	Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo. 2008 , 68, 599-609	17
1639	RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. 2008 , 68, 861-71	59
1638	Expression profiling of CD133+ and CD133- epithelial cells from human prostate. 2008 , 68, 1007-24	60
1637	Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. 2008 , 68, 1105-15	41
1636	Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. 2008 , 68, 1461-6	23
1635	Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. 2008 , 68, 1763-72	28

1634	Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. 2008 , 68, 1753-62	14
1633	Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. 2008 , 112, 326-30	83
1632	A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. 2008 , 112, 521-6	89
1631	Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. 2008 , 112, 1660-71	16
1630	C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. 2008 , 112, 2377-83	88
1629	Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. 2008 , 113, 975-84	166
1628	Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. 2008 , 113, 2478-87	207
1627	Targeted therapy in prostate cancer--are we our own worst enemy?. 2008 , 113, 2376-8	6
1626	Development of drugs against hormone-refractory prostate cancer. 2008 , 69, 431-450	5
1625	EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. 2008 , 122, 595-602	72
1624	Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer. 2008 , 122, 1941-8	26
1623	Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. 2008 , 122, 2368-76	26
1622	Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells. 2008 , 104, 1636-46	24
1621	Perspectives thérapeutiques des métastases osseuses de cancer prostatique. 2008 , 75, 343-351	
1620	Oncogériatrie pratique. 2008 , 75, 542-545	1
1619	Overcoming challenges associated with chemotherapy treatment in the senior adult population. 2008 , 68 Suppl 1, S1-8	29
1618	Adapting treatment for prostate cancer according to risk of disease progression. 2008 , 68 Suppl 1, S23-31	1
1617	Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. 2008 , 68 Suppl 1, S9-S22	26

1616	Salvage therapy for radiorecurrent prostate cancer. 2008 , 32, 242-71	15
1615	Use of a modified hemi-body irradiation technique for metastatic carcinoma of the prostate: report of a 10-year experience. 2008 , 20, 591-8	12
1614	STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial. 2008 , 20, 577-81	34
1613	Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. 2008 , 71, 9-15	13
1612	Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFR-expressing androgen-independent prostate tumor models. 2008 , 71, 237-46	14
1611	The pathogenesis of prostate cancer: from molecular to metabolic alterations. 2008 , 14, 195-201	15
1610	An investigation of fludarabine as a potential radiation sensitizer of human prostate cancer cells in vitro. 2008 , 4, 48-54	1
1609	Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy. 2008 , 98, 238-9	8
1608	A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. 2008 , 98, 894-9	60
1607	Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience. 2008 , 99, 1365-1365	1
1606	Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. 2008 , 99, 2054-64	24
1605	Evidence-based clinical practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition). 2008 , 15, 1-18	14
1604	Third Joint Meeting of the American Urological Association and the Japanese Urological Association International Program at the 103rd Annual Meeting of the American Urological Association at Orlando 2008. 2008 , 15, 1086-1090	
1603	Increased detections of leptomenigeal presentations in men with hormone refractory prostate cancer: an effect of improved systemic therapy?. 2008 , 52, 376-81	17
1602	Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. 2008 , 101, 308-12	37
1601	Chemotherapy in hormone-refractory prostate cancer. 2008 , 101 Suppl 2, 11-5	28
1600	Management of metastatic prostate cancer: the crucial role of geriatric assessment. 2008 , 101 Suppl 2, 23-9	23
1599	Localized prostate cancer: can we better define who is at risk of unfavourable outcome?. 2008 , 101 Suppl 2, 5-10	87

1598	Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. 2008 , 102, 389-97	104
1597	Analysis of complex protein kinase B signalling pathways in human prostate cancer samples. 2008 , 102, 371-82	19
1596	The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. 2008 , 102, 622-7	29
1595	Research in genitourinary oncology: the Canadian Uro-Oncology Group multidisciplinary model. 2008 , 102, 7-8	1
1594	The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. 2008 , 102, 551-5	10
1593	Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. 2008 , 102, 1080-5	28
1592	Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. 2008 , 102, 1607-9	21
1591	A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. 2008 , 102, 1601-6	32
1590	Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. 2008 , 99, 316-23	28
1589	Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. 2008 , 99, 967-72	119
1588	Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. 2008 , 6, 103-9	41
1587	A phase II study of estramustine, docetaxel, and exisulind in patients with hormone-refractory prostate cancer: results of cancer and leukemia group B trial 90004. 2008 , 6, 110-6	9
1586	Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. 2008 , 6, 134-7	6
1585	Overexpression of phospholipase D suppresses taxotere-induced cell death in stomach cancer cells. 2008 , 1783, 912-23	25
1584	Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. 2008 , 53, 323-31	15
1583	Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. 2008 , 53, 331	
1582	Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. 2008 , 53, 332	
1581	Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. 2008 , 53, 6-9	38

1580	EAU guidelines on prostate cancer. 2008 , 53, 68-80	848
1579	Words of wisdom. Re: Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. 2008 , 53, 666-7	
1578	New treatment approaches for prostate cancer based on peptide analogues. 2008 , 53, 890-900	28
1577	Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues. 2008 , 53, 899-900	
1576	Immunotherapy of prostate cancer. 2008 , 53, 681-3; discussion 684-5	3
1575	Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 2008 , 54, 1089-94	106
1574	Editorial comment on: combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 2008 , 54, 1094-6	
1573	Highlights from: The 2008 meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL. 2008 , 6, 65-72	1
1572	Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. 2008 , 42, 91-8	63
1571	Pilot study of rapamycin in patients with hormone-refractory prostate cancer. 2008 , 6, 97-102	47
1570	Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. 2008 , 6, 43	21
1569	Novel therapies in genitourinary cancer: an update. 2008 , 1, 11	1
1568	Rationale for Anti-TGF- β Antibody Therapy in Oncology. 2008 , 757-774	2
1567	Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. 2008 , 5, 506-7	22
1566	Somatic Genetic Changes in Prostate Cancer. 2008 , 99-128	
1565	Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. 2008 , 9, R83	159
1564	[Chemotherapy indications in the treatment of metastases from urological malignancies]. 2008 , 18 Suppl 7, S219-22	0
1563	Current status and future prospects for satraplatin, an oral platinum analogue. 2008 , 14, 1633-8	171

1562	Monoclonal antibody therapy for prostate cancer. 2008 , 237-56	10
1561	ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. 2008 , 17, 1237-45	28
1560	Checkpoint Responses in Cancer Therapy. 2008 ,	1
1559	Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. 2008 ,	2
1558	[Chemotherapy for prostate cancer]. 2008 , 37, 814-20	0
1557	Immunogenicity of anthracyclines: moving towards more personalized medicine. 2008 , 14, 141-51	91
1556	Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. 2008 , 71, 136-40	20
1555	Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. 2008 , 71, 323-7	27
1554	p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). 2008 , 71, 933-7	17
1553	Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer. 2008 , 71, 942-6	12
1552	Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer. 2008 , 71, 1181-5	2
1551	Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. 2008 , 72, 474-80	17
1550	PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer. 2008 , 72, 903-7	13
1549	Nanoparticles for drug delivery in cancer treatment. 2008 , 26, 57-64	522
1548	Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). 2008 , 26, 276-80	31
1547	Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era. 2008 , 26, 408-14	5
1546	Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer. 2008 , 26, 426-9	9
1545	New drug development in metastatic prostate cancer. 2008 , 26, 430-7	16

1544	Dendritic cell vaccines for the treatment of prostate cancer. 2008 , 26, 576-80	6
1543	Local-regional prostate cancer. 2008 , 26, 516-21	4
1542	Current status of experimental therapeutics for prostate cancer. 2008 , 266, 116-34	38
1541	When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?. 2008 , 44, 1193-7	25
1540	Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases. 2008 , 12, 283-90	24
1539	Targeting the androgen receptor pathway in prostate cancer. 2008 , 8, 440-8	330
1538	New research findings on zoledronic acid: survival, pain, and anti-tumour effects. 2008 , 34, 183-92	58
1537	The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. 2008 , 34, 710-8	47
1536	Radioterapia adyuvante en el c�ncer de pr�stata. 2008 , 40, 1-9	
1535	Anticancer Drugs That Inhibit Hormone Action. 2008 , 53-91	3
1534	Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. 2008 , 26, 1148-59	1651
1533	Prostate cancer stem cells: a new target for therapy. 2008 , 26, 2862-70	261
1532	[Effectiveness of bisphosphonates in advanced prostate cancer]. 2008 , 130, 459-62	0
1531	Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. 2008 , 89, 205-13	72
1530	Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007. 2008 , 7, 460-476	0
1529	Prostate Cancer: When the Hormonal Treatment Is No Longer Working. 2008 , 7, 416-421	
1528	Prostate cancer. 2008 , 371, 1710-21	395
1527	Docetaxel for hormone-refractory prostate cancer. 2008 , 372, 1461; author reply 1461-2	1

1526	Trials in palliative treatment--have the goal posts been moved?. 2008 , 9, 186-7	30
1525	Off-label use of anticancer drugs. 2008 , 9, 1102-7	64
1524	[Chemotherapy of hormonorefractory and hormono-resistant metastatic prostate cancer]. 2008 , 18 Suppl 7, S365-75	5
1523	Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. 2008 , 179, 911-5; discussion 915-6	24
1522	Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. 2008 , 180, 565-70; discussion 570	97
1521	A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy. 2008 , 1, 141-7	28
1520	Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. 2008 , 179, 117-22; discussion 122-3	21
1519	[Pain and bone metastases]. 2008 , 18 Suppl 7, S399-409	8
1518	Prostate cancer vaccines: current status and future potential. 2008 , 22, 71-84	19
1517	Measuring the individual quality of life of patients with prostate cancer. 2008 , 11, 390-6	15
1516	Docetaxel in the management of prostate cancer: current standard of care and future directions. 2008 , 9, 1969-79	12
1515	Ixabepilone for the treatment of solid tumors: a review of clinical data. 2008 , 17, 423-35	15
1514	Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer?. 2008 , 42, 116-20	4
1513	Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. 2008 , 7, 19-26	70
1512	Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. 2008 , 100, 681-2; author reply 682-3	2
1511	The postchemotherapy PSA surge syndrome. 2008 , 19, 1308-1311	55
1510	Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. 2008 , 19, 1624-8	42
1509	Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2008 , 19 Suppl 2, ii45-6	13

1508	Novel tracers and their development for the imaging of metastatic prostate cancer. 2008 , 49, 2031-41	109
1507	The role of chemotherapy at the end of life: "when is enough, enough?". 2008 , 299, 2667-78	197
1506	Angiogenesis. 2008 ,	25
1505	Efficacy vs. effectiveness--docetaxel and prednisone in hormone refractory prostate cancer. 2008 , 14, 45-9	7
1504	Chemotherapy for advanced prostate cancer: 25 years later. 2008 , 26, 2423-4	5
1503	ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. 2008 , 14, 4543-9	117
1502	EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. 2008 , 7, 3176-86	50
1501	Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. 2008 , 26, 5261-8	67
1500	A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. 2008 , 14, 6270-6	61
1499	Access to cancer drugs: local autonomy or local tyranny?. 2008 , 69, 436-7	
1498	Oral vinorelbine as first line chemotherapy in unfit elderly patients with hormone-refractory prostate cancer. 2008 , 20, 368-73	2
1497	Radical prostatectomy in the 21st century - the gold standard for localized and locally advanced prostate cancer. 2008 , 41, 7-14	13
1496	Radiotherapy as primary treatment modality. 2008 , 41, 15-25	4
1495	Recurrence following radiotherapy. 2008 , 41, 86-92	2
1494	Chemotherapy in hormone-refractory prostate cancer. 2008 , 41, 103-107	3
1493	Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. 2008 , 74, 223-8	19
1492	Combining ¹⁵³ Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience. 2008 , 23, 609-18	19
1491	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. 2008 , 26, 242-5	824

1490	Urological Oncology. 2008 ,	2
1489	A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. 2008 , 98, 22-4	26
1488	Update in systemic therapy of prostate cancer: improvement in quality and duration of life. 2008 , 8, 269-81	11
1487	Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. 2008 , 14, 1150-8	51
1486	Early chemotherapy in prostate cancer. 2008 , 5, 486-93	14
1485	GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. 2008 , 14, 5769-77	52
1484	The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. 2008 , 283, 20635-44	92
1483	Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). 2008 , 7, 974-82	60
1482	Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. 2008 , 7, 2649-61	77
1481	A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. 2008 , 14, 7940-6	148
1480	Is chemotherapy the standard for asymptomatic androgen-independent prostate cancer?. 2008 , 26, 2413-4; author reply 2414-5	3
1479	Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. 2008 , 26, 2959-65	27
1478	Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. 2008 , 19, 269-75	18
1477	A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. 2008 , 19, 746-51	100
1476	Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study. 2008 , 11, 181-6	17
1475	Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. 2008 , 19, 1749-53	86
1474	Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. 2008 , 38, 365-72	68
1473	Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. 2008 , 19 Suppl 7, vii91-5	24

1472	TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. 2008 , 68, 3440-9	38
1471	RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. 2008 , 7, 2160-9	71
1470	Opioids in context: relieving the pain of cancer. The role of comprehensive cancer management. 2008 , 22, 303-9	8
1469	Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. 2008 , 26, 5936-42	69
1468	Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. 2008 , 14, 2763-7	160
1467	Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. 2008 , 26, 2544-9	147
1466	Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?. 2008 , 26, 6-8	46
1465	An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. 2008 , 14, 5255-9	74
1464	Randomized, double-blinded phase II evaluation of docetaxel with or without doxercaliferol in patients with metastatic, androgen-independent prostate cancer. 2008 , 14, 2437-43	51
1463	Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. 2008 , 29, 234-52	45
1462	Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. 2008 , 7, 1836-45	98
1461	Rapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past?. 2008 , 26, 2932-3	0
1460	Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. 2008 , 26, 2147-54	120
1459	Perspective on "Chemotherapy for advanced prostate cancer: 25 years later": is it a mirage or an oasis?. 2008 , 26, 4049-50; author reply 4051	2
1458	The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. 2008 , 17, 23-9	29
1457	Molecular targeting agents in renal cell carcinoma: present strategies and future perspectives. 2008 , 14, 1058-77	6
1456	Lessons learned from development of docetaxel. 2008 , 4, 1007-19	6
1455	Prostate cancer management—helping your patient choose what is best for him. 2008 , 50, 27-34	1

1454	Indium-111 capromab pendetide in the management of recurrent prostate cancer. 2008 , 8, 175-81	49
1453	Cancer in the older person. 2008 , 18, 313-321	
1452	Medical approach to advanced prostate cancer in older patients. 2008 , 4, 481-494	1
1451	Osteoclast-targeted therapy for metastatic prostate cancer. 2008 , 5, 63-72	5
1450	Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. 2008 , 2, 161-6	16
1449	Promising novel cytotoxic agents and combinations in metastatic prostate cancer. 2008 , 14, 15-9	10
1448	Cancer de la prostate hormonorřistant. 2008 , 1, 1-7	
1447	Metastatic prostate cancer mimicking primary osteosarcoma of the jaw: an infrequent clinical case. 2008 , 101, 657-9	5
1446	Novel approaches for the treatment of prostate cancer. 2008 , 5, 1-2	2
1445	Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life. 2008 , 19, 645-53	7
1444	Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer. 2008 , 31, 188-94	2
1443	Clinical endpoints for drug development in prostate cancer. 2008 , 18, 303-8	15
1442	The role of angiogenesis inhibitors in prostate cancer. 2008 , 14, 20-5	27
1441	Current controversies in the treatment of high-risk prostate cancer. 2008 , 18, 263-8	18
1440	Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. 2008 , 31, 532-8	27
1439	Cell signaling modifiers in prostate cancer. 2008 , 14, 40-5	7
1438	Prostate. 231-239	
1437	Doenřas da prřstata. 2008 , 87, 166	1

1436	Multi-faceted roles for CXC-chemokines in prostate cancer progression. 2008 , 13, 4595-604	43
1435	Docetaxel chemotherapy of Korean patients with hormone- refractory prostate cancer:comparative analysis between 1st-line and 2nd-line docetaxel. 2008 , 49, 775-82	8
1434	Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group. 2008 , 15, 179-84	4
1433	Management of advanced prostate cancer. 2008 , 54, 178-82	8
1432	Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. 2007 , 2, 555-60	12
1431	Dietary terpenoids and prostate cancer chemoprevention. 2008 , 13, 3457-69	25
1430	Systemic therapy. 93-101	
1429	Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015. 2008 , 4, 79-85	5
1428	Metastatic Hormonorefractory Prostate Cancer: Treatment of Disease Progression after Taxanes Based Chemotherapy. 2009 , 76, 59-63	
1427	[Therapy related leukemia with 11q23 abnormality induced by chemotherapy consisted of docetaxel for advanced prostatic carcinoma: case report]. 2009 , 100, 580-5	2
1426	Hormone Refractory Prostate Cancer: Focus on Sipuleucel-T. 2009 , 1, CMT.S1084	
1425	Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC). 2009 , 10, 493-501	6
1424	A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. 2009 , 24, 175-80	39
1423	Finding the place of histone deacetylase inhibitors in prostate cancer therapy. 2009 , 2, 619-30	4
1422	Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. 2009 , 15, 7421-8	192
1421	Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2009 , 20 Suppl 4, 76-8	17
1420	Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?. 2009 , 9, 939-51	6
1419	Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. 2009 , 69, 1527-35	62

1418	Targeting the PI3K/AKT pathway for the treatment of prostate cancer. 2009 , 15, 4799-805	272
1417	Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. 2009 , 27, 2766-71	81
1416	Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. 2009 , 15, 5389-95	43
1415	Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. 2009 , 20, 703-8	48
1414	Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. 2009 , 101, 263-8	84
1413	Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. 2009 , 101, 1248-52	38
1412	Phase II study of sunitinib in men with advanced prostate cancer. 2009 , 20, 913-20	122
1411	Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. 2009 , 20, 498-502	8
1410	Castration-resistant prostate cancer: locking up the molecular escape routes. 2009 , 15, 3251-5	159
1409	The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. 2009 , 12, 88-93	22
1408	Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. 2009 , 27, 3319-24	42
1407	In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. 2009 , 15, 39-47	115
1406	Expression of immunosuppressive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. 2009 , 15, 2174-80	64
1405	COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER. 2009 , 1, 69-77	2
1404	Immunotherapy for prostate cancer: walk, don't run. 2009 , 27, 4035-7	32
1403	PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report. 2009 , 2, 72-76	1
1402	Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. 2009 , 76, 442-6	23
1401	Phosphorylation status of Fas-associated death domain-containing protein regulates telomerase activity and strongly correlates with prostate cancer outcomes. 2009 , 76, 293-302	8

1400	Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer. 2009 , 9, 1058-69	8
1399	Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. 2009 , 1, 7-11	12
1398	Surgical management of prostate cancer metastatic to the spine. 2009 , 10, 414-22	46
1397	Satraplatin for the therapy of castration-resistant prostate cancer. 2009 , 5, 931-40	7
1396	Dendritic-cell vaccination for prostate cancer. 2009 , 1, 63-72	1
1395	An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. 2009 , 15, 3172-6	146
1394	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. 2009 , 18, 1001-11	161
1393	Angiogenesis inhibition in the treatment of prostate cancer. 2009 , 9, 1070-8	6
1392	Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. 2009 , 17, 430-8	100
1391	Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. 2009 , 27, 2772-8	30
1390	Die Behandlung des fortgeschrittenen, unheilbaren Prostatakarzinoms – Möglichkeiten einer medikamentösen und palliativen Therapie. 2009 , 38, 400-403	
1389	Toxizität und Effektivität wiederholter Docetaxeltherapie des hormonrefraktären Prostatakarzinoms. 2009 , 30, 257-261	
1388	Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. 2009 , 13, 1449-58	59
1387	The quest for the 'bony Grail' of detecting circulating tumour cells in patients with prostate cancer. 2009 , 20, 197-9	4
1386	Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. 2009 , 12, 241-6	22
1385	Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. 2009 , 20, 1264-9	93
1384	Prostatakarzinom. 2009 , 485-635	
1383	Prostate cancer chemotherapy in the era of targeted therapy. 2009 , 12, 13-6	27

1382	A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. 2009 , 20, 1971-6	12
1381	Emerging drugs for prostate cancer. 2009 , 14, 455-70	5
1380	Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. 2009 , 27, 2436-42	79
1379	Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. 2009 , 20, 492-7	44
1378	Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. 2009 , 20, 965	18
1377	Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates. 2009 , 15, 865-75	23
1376	The Role of Chemotherapy in the Treatment of Bone Metastases. 2009 , 287-298	5
1375	Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. 2009 , 69, 7696-703	86
1374	Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?. 2009 , 27, 2417-8	7
1373	High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. 2009 , 15, 6070-8	148
1372	Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. 2009 , 15, 4954-62	74
1371	Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. 2009 , 27, 2429-35	135
1370	Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. 2009 , 27, 5431-8	268
1369	MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. 2009 , 15, 5126-35	80
1368	Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer. 2009 , 18, 275-82	7
1367	Adjuvant therapy after radical prostatectomy: clinical considerations. 2009 , 18, 247-54	2
1366	Future directions in non-endocrine systemic treatment of metastatic prostate cancer. 2009 , 18, 283-8	0
1365	Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. 2009 , 348, 9-17	180

1364	MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. 2009 , 9, 142	38
1363	Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. 2009 , 55, 1368-75	96
1362	Editorial comment on: Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. 2009 , 55, 1375-6	
1361	Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail?. 2009 , 55, 1310-2	7
1360	Rebuttal from authors re: Joaquim Bellmunt. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol 2009;55:1310-2. 2009 , 55, 1313-4	1
1359	Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. 2009 , 55, 1112-23	125
1358	A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. 2009 , 56, 97-103	47
1357	Editorial comment on: A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. 2009 , 56, 103-4	1
1356	Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. 2009 , 56, 594-605	123
1355	Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. 2009 , 125, 2728-36	41
1354	Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. 2009 , 125, 2711-20	10
1353	PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. 2009 , 4, 1302-10	102
1352	Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. 2009 , 115, 784-91	36
1351	Genomic approaches to outcome prediction in prostate cancer. 2009 , 115, 3046-57	16
1350	Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. 2009 , 115, 5541-9	107
1349	Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. 2009 , 14, 130-5	13
1348	Recherche clinique en oncogfiatrie. 2009 , 11, 331-336	
1347	Schmerztherapie bei onkologischen Patienten. 2009 , 15, 663-668	

1346	Predictive modelling in hormone-refractory prostate cancer (HRPC). 2009 , 11, 82-5	4
1345	(18)F-Choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer. 2009 , 23, 541-8	18
1344	Does chemotherapy have a role before hormone-resistant disease develops?. 2009 , 10, 226-35	
1343	Prostate cancer targeted MRI nanoprobe based on superparamagnetic iron oxide and copolymer of poly(ethylene glycol) and polyethyleneimin. 2009 , 54, 3137-3146	12
1342	[Secondary hormonal ablation in hormone-independent prostate cancer]. 2009 , 48, 183-8; quiz 189-90	2
1341	[Immunomodulatory treatment approaches for prostate cancer]. 2009 , 48, 755-63	1
1340	[Patients with metastatic hormone-refractory prostate cancer. Second-line chemotherapy with mitoxantrone plus prednisone]. 2009 , 48, 1070-4	1
1339	[Uro-oncology--update 2009]. 2009 , 48, 1056-8	
1338	[Palliative systemic therapy of castration-resistant prostate cancer: current developments]. 2009 , 48, 1295-301	
1337	Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. 2009 , 36, 1434-42	43
1336	(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. 2009 , 36, 1425-33	27
1335	NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. 2009 , 63, 303-12	16
1334	Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer. 2009 , 64, 407-12	2
1333	The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. 2009 , 69, 142-8	7
1332	Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. 2009 , 69, 744-54	18
1331	Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. 2009 , 69, 1101-8	111
1330	Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts. 2009 , 69, 1151-63	24
1329	Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. 2009 , 69, 1448-59	62

1328	Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. 2009 , 69, 1579-85	76
1327	PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy. 2009 , 69, 1802-7	35
1326	Differential phosphoprotein levels and pathway analysis identify the transition mechanism of LNCaP cells into androgen-independent cells. 2010 , 70, 508-17	6
1325	Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. 2009 , 10, 39	95
1324	Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. 2009 , 100, 144-9	28
1323	Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. 2009 , 100, 2109-14	25
1322	Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. 2009 , 11, 443-50	16
1321	Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. 2009 , 28, 2849-59	24
1320	Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. 2009 , 100, 13-8	43
1319	Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. 2009 , 100, 649-55	14
1318	Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. 2009 , 101, 951-6	61
1317	Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. 2009 , 101, 1233-40	56
1316	Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. 2009 , 101, 1731-9	14
1315	Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors. 2009 , 16, 670-5	6
1314	Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. 2009 , 16, 687-91	17
1313	Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival. 2009 , 16, 726-31	8
1312	Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. 2009 , 16, 731-2	
1311	Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. 2009 , 103, 464-9	58

1310	The role of systemic cytotoxic therapy for prostate cancer. 2009 , 103, 8-17	23
1309	What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?. 2009 , 103, 1641-6	27
1308	Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. 2009 , 103, 1636-40	102
1307	Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. 2009 , 104, 107-14	15
1306	A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. 2009 , 104, 1098-102	30
1305	Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. 2009 , 104, 438-48	59
1304	Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer. 2009 , 104, 1423-5	16
1303	Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. 2009 , 73, 672-8	48
1302	Thirty-day mortality for patients with genitourinary malignancies being treated with chemotherapy. 2009 , 21, 730	4
1301	Prognosis of patients with triple-negative breast cancer and brain metastasis. 2009 , 21, 729-30	8
1300	Taxanes in the elderly: can we gain as much and be less toxic?. 2009 , 70, 262-71	16
1299	External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months. 2009 , 74, 759-65	12
1298	Management of prostate cancer: future treatment approaches. 2009 , 10, 9-12	1
1297	Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. 2009 , 8, 3044-54	51
1296	Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. 2009 , 8, 1655-65	28
1295	[Recommendations for the treatment of prostate cancer in the elderly man: A study by the oncology committee of the French association of urology]. 2009 , 19, 810-7	3
1294	Treatment of prostate cancer in unfit senior adult patients. 2009 , 35, 522-7	18
1293	Docetaxel-related side effects and their management. 2009 , 13, 49-59	160

1292	Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. 2009 , 71, 409-19	944
1291	Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis. 2009 , 276, 21-31	20
1290	Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. 2009 , 138, 245-56	691
1289	Prostate tumor-initiating cells: a new target for telomerase inhibition therapy?. 2009 , 1792, 289-96	23
1288	Systemic therapy and novel agents for metastatic castration resistant prostate cancer. 2009 , 3, 133-145	2
1287	Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel. 2009 , 73, 1407-11	33
1286	Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial. 2009 , 74, 665-71	33
1285	A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. 2009 , 27, 165-9	7
1284	Positive surgical margins: the argument for androgen deprivation and chemotherapy. 2009 , 27, 89-91	
1283	Optimal timing of chemotherapy in androgen independent prostate cancer. 2009 , 27, 97-100	5
1282	EAU-a work in progress-what comes next?. 2009 , 27, 125-6	
1281	A medical oncologist's perspective on the treatment of patients with genitourinary malignancies. 2009 , 27, 122-5	0
1280	New opportunities in the management of prostate cancer-related bone complications. 2009 , 27, S1-S20	4
1279	Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. 2009 , 62, 13-21.e5	91
1278	Vitamin D and intervention trials in prostate cancer: from theory to therapy. 2009 , 19, 96-102	41
1277	Modern Chemotherapy Strategies for Management of Hormone Resistant Prostate Cancer When Should the Urologist Refer?. 2009 , 2, 92-99	2
1276	New therapeutic agents for castration-refractory prostate cancer. 2009 , 7, E4-6	0
1275	Clusterin (CLU) and prostate cancer. 2009 , 105, 1-19	29

1274	Clusterin and chemoresistance. 2009 , 105, 77-92	81
1273	Androgen Action in Prostate Cancer. 2009 ,	6
1272	Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. 2009 , 69, 8386-94	161
1271	[EAU guidelines on prostate cancer]. 2009 , 33, 113-26	45
1270	Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. 2009 , 6, 85-92	20
1269	Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy. 2009 , 9, 953-62	0
1268	Palliative prostate radiotherapy for symptomatic advanced prostate cancer. 2009 , 93, 192-6	32
1267	Introduction. 2009 , 8, 1-3	
1266	Highlighting Unmet Needs: Real Patients, Difficult Choices. 2009 , 8, 4-12	
1265	Issues with the Use of Prostate-Specific Antigen as a Surrogate End Point in Hormone-Resistant Prostate Cancer. 2009 , 8, 13-19	7
1264	Challenges and Opportunities in Hormone-Resistant Prostate Cancer. 2009 , 8, 36-45	4
1263	Integrating Molecular Oncology into Therapeutic Strategies for Prostate Cancer. 2009 , 8, 114-119	2
1262	Role of Chemotherapy in Nonmetastatic Hormone-Refractory Prostate Cancer. 2009 , 8, 448-452	2
1261	Management of High-Risk Localised Prostate Cancer. 2009 , 8, 439-447	1
1260	Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. 2009 , 8, 738-746	4
1259	Advances in the Therapy of Prostate Cancer-Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways. 2009 , 8, 747-752	2
1258	Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. 2009 , 100, 914-9	37
1257	Novel biomarkers for prostate cancer including noncoding transcripts. 2009 , 175, 2264-76	89

1256	Clinical studies with epothilones. 2009 , 90, 221-37	0
1255	Satraplatin: leading the new generation of oral platinum agents. 2009 , 18, 1787-97	73
1254	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. 2009 , 10, 233-9	476
1253	Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. 2009 , 10, 981-91	235
1252	Chemotherapy in patients with castration-resistant prostate cancer. 2009 , 45 Suppl 1, 161-71	10
1251	New agents in metastatic prostate cancer. 2009 , 45 Suppl 1, 379-80	4
1250	The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. 2009 , 27, 331-5	33
1249	Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. 2009 , 181, 2520-4; discussion 2525	29
1248	HE3235 inhibits growth of castration-resistant prostate cancer. 2009 , 11, 1216-25	16
1247	Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. 2009 , 181, 956-62	916
1246	Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. 2009 , 181, 1672-7; discussion 1677	38
1245	Urological Oncology: Prostate Cancer. 2009 , 181, 1121-1124	0
1244	[Prostate cancer: evidence based clinical practice]. 2009 , 33, 344-50	9
1243	Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. 2009 , 182, 317-23	13
1242	Patient selection for phase II trials. 2009 , 32, 216-9	5
1241	Response rates: a valuable signal of promising activity?. 2009 , 15, 361-5	5
1240	VEGF inhibitors and prostate cancer therapy. 2009 , 2, 161-8	44
1239	Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: A phase II study. 2009 ,	

1238	The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer. 2009 , 23,	5
1237	Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. 2009 , 117, 209-28	25
1236	Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binominal regression for febrile neutropenia. 2009 , 129, 749-57	9
1235	The management of metastatic prostate cancer. 2009 , 3, 93-103	4
1234	The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. 2009 , 7 Suppl 7, S1-29; quiz S30	67
1233	Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. 2009 , 9, 237-49	198
1232	In Reply. 2009 , 27, 1149-1150	2
1231	Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer. 2010 , 3, 121-7	2
1230	Assessing older prostate cancer patients for chemotherapy: recommendations from the International Society of Geriatric Oncology. 2010 , 6, 365-369	
1229	A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. 2010 , 21, 433-8	34
1228	A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer. 2010 , 21, 927-31	3
1227	Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. 2010 , 17, 176-81	6
1226	Current status of immunological therapies for prostate cancer. 2010 , 20, 241-6	36
1225	Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. 2010 , 16, 1-9	128
1224	High-risk localized prostate cancer: role of radical prostatectomy. 2010 , 20, 204-10	11
1223	Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy. 2010 , 58, 566-568	14
1222	Investigation of risk factors for prostate cancer patients with bone metastasis based on clinical data. 2010 , 1, 635-639	4
1221	[Effects of bioactive molecules of <i>Beta vulgaris</i> L. ssp. <i>esculenta</i> var. <i>rubra</i> on metastatic prostate cancer]. 2010 , 151, 1495-503	3

1220	NCCN clinical practice guidelines in oncology: prostate cancer. 2010 , 8, 162-200	555
1219	Paradoxical response of prostate cancer skeletal metastases to androgen deprivation therapy. 2010 , 5, 443	1
1218	A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line. 2010 , 34, 177-84	26
1217	Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. 2010 , 37, 15-20	54
1216	[Research and development of hormone-related anti-prostate cancer drugs-17, 20-lyase inhibitors for prostate cancer]. 2010 , 136, 192-7	1
1215	Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. 2010 , 7, 101-8	11
1214	Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. 2010 , 19, 605-14	29
1213	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. 2010 , 59, 663-74	249
1212	A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. 2010 , 59, 1001-9	86
1211	Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. 2010 , 66, 295-301	9
1210	A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. 2010 , 66, 845-50	30
1209	A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. 2010 , 66, 181-9	98
1208	[What comes after docetaxel?]. 2010 , 49, 64-8	0
1207	[Systemic treatment of metastatic prostate cancer]. 2010 , 49, 221-7	1
1206	Modular therapy approach in metastatic castration-refractory prostate cancer. 2010 , 28, 745-50	11
1205	Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. 2010 , 31, 7355-63	98
1204	Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980-2007. 2010 , 34, 359-67	14
1203	Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer. 2010 , 16, 200-5	6

1202	Vinflunin in der Zweitlinienbehandlung des Urothelkarzinoms. 2010 , 16, 523-526	
1201	Practice changing data and new developments in the management of prostate cancer âASCO 2010. 2010 , 3, 164-166	
1200	Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. 2010 , 27, 363-7	48
1199	Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment. 2010 , 12, 346-55	6
1198	Contemporary management of high-risk localized prostate cancer. 2010 , 11, 159-64	11
1197	Emerging therapies in castrate-resistant prostate cancer. 2010 , 11, 152-8	14
1196	Update: immunological strategies for prostate cancer. 2010 , 11, 202-7	27
1195	Mammographiescreening. 2010 , 5, 4-14	
1194	Phenethyl isothiocyanate sensitizes androgen-independent human prostate cancer cells to docetaxel-induced apoptosis in vitro and in vivo. 2010 , 27, 722-31	34
1193	Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. 2010 , 28, 291-8	13
1192	Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. 2010 , 147, 278-88	69
1191	Changing therapeutic paradigms in castrate-resistant prostate cancer. 2010 , 8, 17-22	10
1190	Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. 2010 , 8, 23-8	10
1189	Contemporary therapeutic approaches targeting bone complications in prostate cancer. 2010 , 8, 29-36	16
1188	Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. 2010 , 10, 511	38
1187	Angiogenesis inhibitors in the treatment of prostate cancer. 2010 , 3, 26	39
1186	Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse model. 2010 , 41, 369-75	24
1185	Words of wisdom. Re: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Scher HI, Beer TM, Higano CS, et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. 2010 , 58, 464-5	5

1184	Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole GL, Bostwick DG, Brawley OW, et al. 2010 , 58, 465-6	
1183	An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers. 2010 , 32, 1372-86	4
1182	A novel anticancer agent, retigeric acid B, displays proliferation inhibition, S phase arrest and apoptosis activation in human prostate cancer cells. 2010 , 188, 598-606	23
1181	Vaccines as monotherapy and in combination therapy for prostate cancer. 2010 , 3, 116-22	9
1180	Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. 2010 , 116, 1075-83	109
1179	Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. 2010 , 116, 1699-708	30
1178	A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. 2010 , 116, 3595-602	19
1177	CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide. 2010 , 127, 2020-30	37
1176	Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution. 2010 , 12, 516-27	5
1175	Angiogenesis as a strategic target for prostate cancer therapy. 2010 , 30, 23-66	30
1174	Promising tumor-associated antigens for future prostate cancer therapy. 2010 , 30, 67-101	23
1173	Frequency of screening magnetic resonance imaging to detect occult spinal cord compromise and to prevent neurological deficit in metastatic castration-resistant prostate cancer. 2010 , 22, 147-52	10
1172	Ductal variant of adenocarcinoma prostate responding to docetaxel--a case report. 2010 , 22, 617	4
1171	Counterpoint: Prostate carcinoma treatment for the young patient--The case for radical prostatectomy. 2010 , 9, 195-8; discussion 199-201	1
1170	Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. 2010 , 73, 68-91	78
1169	Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer. 2010 , 76, 1085-91	5
1168	Tumours of the prostate. 2010 , 10,	78
1167	Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. 2010 , 70, 27-36	40

1166	CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. 2010 , 70, 48-60	23
1165	Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels. 2010 , 70, 179-89	24
1164	Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer. 2010 , 70, 616-29	5
1163	A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species. 2010 , 70, 1074-86	56
1162	The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. 2010 , 11, 337-46	124
1161	Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. 2010 , 58, 986-8	23
1160	Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. 2010 , 13, 613-23	24
1159	Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. 2010 , 6, 42-8	36
1158	A phase II trial of weekly i.v. KW-2170 in advanced castrate-resistant prostate cancer. 2010 , 6, 292-7	3
1157	Differential expression of estrogen-related receptors beta and gamma (ERRbeta and ERRgamma) and their clinical significance in human prostate cancer. 2010 , 101, 646-51	32
1156	Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. 2010 , 101, 601-8	9
1155	5alphaDH-DOC (5alpha-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer. 2010 , 101, 1897-904	14
1154	Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. 2010 , 29, 1883-96	105
1153	Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL. 2010 , 17, 180-91	11
1152	Sipuleucel-T. 2010 , 9, 513-4	113
1151	Prostate cancer as a model for tumour immunotherapy. 2010 , 10, 580-93	272
1150	Role of targeted therapy in the treatment of advanced prostate cancer. 2010 , 105, 748-67	22
1149	Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. 2010 , 106, 974-8	66

1148	Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. 2010 , 106, 462-9	145
1147	Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. 2010 , 106, 966-73	81
1146	The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. 2010 , 17, 228-40	7
1145	Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients. 2010 , 17, 629-34	9
1144	Chemotherapy for hormone-refractory prostate cancer: a physician's dilemma. 2010 , 40, 864-5	
1143	Pharmacology and unique side effects of chemotherapy in older adults. 18-31	1
1142	Management of prostate cancer in older adults. 186-200	
1141	EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment. 2010 , 3, 2238-2247	27
1140	Angiogenesis inhibition in prostate cancer: current uses and future promises. 2010 , 2010, 361836	24
1139	Multimodal approaches to high-risk prostate cancer. 2010 , 17 Suppl 2, S33-7	11
1138	Research in castration-resistant prostate cancer: what does the future hold?. 2010 , 17 Suppl 2, S80-6	8
1137	Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient. 2010 , 3, 39-41	2
1136	Salvage chemotherapy for hormone-refractory prostate cancer: Association of Adriamycin and ifosfamide. 2010 , 1, 1005-1011	
1135	Second-Line Antiandrogen Therapy in Japanese Men with Advanced Prostate Cancer Relapsed after Primary Combined Androgen Blockade: Who Will Benefit from Second-Line Hormonal Therapy?. 2010 , 85, 491-497	
1134	Recovery of hormone sensitivity after salvage brachytherapy for hormone refractory localized prostate cancer. 2010 , 36, 283-91	3
1133	A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital. 2010 , 17, 24-9	20
1132	Oral low-dose dexamethasone for androgen-independent prostate cancer patients. 2010 , 1, 73-79	15
1131	Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. 2010 , 2, 111-22	15

1130	Critical appraisal of cabazitaxel in the management of advanced prostate cancer. 2010 , 5, 395-402	23
1129	Update on options for treatment of metastatic castration-resistant prostate cancer. 2010 , 3, 39-51	21
1128	Docetaxel and Prednisone (DP) for Advanced Prostate Cancer. 2010 , 45, 293-302	
1127	Efficacy and toxicity of mitoxantrone and oral etoposide in the treatment of hormone-refractory prostate cancer: pilot study. 2010 , 8, 336-8	1
1126	Complete androgen blockade safely allows for delay of cytotoxic chemotherapy in castration refractory prostate cancer. 2010 , 36, 300-7	3
1125	Current management of castrate-resistant prostate cancer. 2010 , 17 Suppl 2, S72-9	151
1124	Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. 2010 , 21, 312-318	32
1123	Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. 2010 , 28, 4562-7	73
1122	Castration-resistant prostate cancer--hormone therapy redux. 2010 , 28, 1447-9	6
1121	Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. 2010 , 6, 665-79	20
1120	Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. 2010 , 28, 2070-6	126
1119	Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. 2010 , 70, 9253-64	116
1118	Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. 2010 , 28, 1489-95	331
1117	Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. 2010 , 70, 1256-64	140
1116	Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer. 2010 , 44, 1538-44	4
1115	Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. 2010 , 28, 1481-8	325
1114	Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. 2010 , 70, 7992-8002	278
1113	A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. 2010 , 21, 305-311	17

1112	Is there a role for chemotherapy in nonmetastatic prostate cancer?. 2010 , 4, 141-6	1
1111	ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. 2010 , 70, 3239-48	98
1110	Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. 2010 , 16, 3028-34	154
1109	Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past. 2010 , 16, 5963-71	20
1108	Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells. 2010 , 38, 1663-72	2
1107	The Scientific Basis of Urology. 2010 ,	9
1106	Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. 2010 , 102, 522-8	177
1105	Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). 2010 , 21, 109-13	131
1104	Dendritic cell-based immunotherapy for prostate cancer. 2010 , 2010, 517493	53
1103	Docetaxel-based combination therapy for castration-resistant prostate cancer. 2010 , 21, 2135-2144	102
1102	Treatment strategies for high-risk locally advanced prostate cancer. 2010 , 7, 31-8	40
1101	Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. 2010 , 28, 4247-54	195
1100	Angiogenesis inhibitors in the treatment of prostate cancer. 2010 , 11, 233-47	29
1099	Presentation, treatment, and outcomes of dural metastases in men with metastatic castrate-resistant prostate cancer: a case series. 2010 , 13, 1125-9	12
1098	Novel targeted agents on the horizon for castration-resistant prostate cancer. 2010 , 6, 1883-95	4
1097	Redefining hormone resistance in prostate cancer. 2010 , 2, 107-123	32
1096	Castration-resistant prostate cancer: new science and therapeutic prospects. 2010 , 2, 189-207	19
1095	Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. 2010 , 9, 617-30	52

1094	Docetaxel in combination with prednisolone for hormone refractory prostate cancer. 2010 , 40, 79-84	13
1093	Genomic predictors of prostate cancer therapy outcomes. 2010 , 10, 619-36	4
1092	Drug Management of Prostate Cancer. 2010 ,	3
1091	Horizon scanning for novel therapeutics for the treatment of prostate cancer. 2010 , 21 Suppl 7, vii43-55	9
1090	Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. 2010 , 10, 543-8	43
1089	5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. 2010 , 10, 281-7	15
1088	Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. 2010 , 16, 4319-24	59
1087	Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. 2010 , 16, 4675-80	39
1086	Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. 2010 , 16, 203-11	163
1085	Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. 2010 , 21, 319-324	109
1084	Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer. 2010 , 2010, 395720	4
1083	Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. 2010 , 13, 108-16	17
1082	Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life. 2010 , 13, 97-101	6
1081	Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. 2010 , 21, 1302-1307	42
1080	Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. 2010 , 15, 969-75	116
1079	Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience. 2010 , 40, 1092-8	23
1078	Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. 2010 , 21, 1864-1869	32
1077	Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. 2010 , 9, 336-46	295

1076	Modulation of the anti-cancer efficacy of microtubule-targeting agents by cellular growth conditions. 2010 , 9, 809-18	9
1075	Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study. 2010 , 78, 323-8	3
1074	Castration refractory prostate cancer: cinderella finally comes to the ball. 2010 , 33, 655-6	
1073	Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. 2010 , 1, e75	144
1072	A new therapy paradigm for prostate cancer founded on clinical observations. 2010 , 16, 1100-7	30
1071	Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer. 2010 , 3, 785-95	6
1070	Sipuleucel-T immunotherapy for castration-resistant prostate cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 1966-7; author reply 1968	59.2 28
1069	Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy. 2010 , 40, 1154-8	2
1068	Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies. 2010 , 10, 137-51	11
1067	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. 2010 , 10, 19-28	26
1066	Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. 2010 , 18, 929-35	29
1065	Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. 2010 , 31, 867-73	117
1064	Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells. 2010 , 9, 1831-41	45
1063	Castrate-resistant prostate cancer: therapeutic strategies. 2010 , 11, 937-45	11
1062	[Chemotherapy in early stage of hormone-resistant metastatic prostate cancer: what are the indications?]. 2010 , 20 Suppl 3, S192-7	
1061	[Update on the use of estramustin in metastatic prostate cancer]. 2010 , 20, 24-9	1
1060	[Recommendations Onco-Urology 2010: Prostate cancer]. 2010 , 20 Suppl 4, S217-51	45
1059	New developments in the medical management of prostate cancer. 2010 , 85, 77-86	55

1058	Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. 2010 , 184, 2557-64	23
1057	Novel targeted therapies for prostate cancer. 2010 , 37, 105-19, Table of Contents	8
1056	Evolving role of bone biomarkers in castration-resistant prostate cancer. 2010 , 12, 685-96	35
1055	Immunotherapy for prostate cancer: an emerging treatment modality. 2010 , 37, 121-9, Table of Contents	9
1054	[Update about advanced prostate cancer: diagnosis, treatment and ongoing perspectives]. 2010 , 20 Suppl 3, S198-202	0
1053	Therapeutic targeting of the prostate cancer microenvironment. 2010 , 7, 494-509	92
1052	Neoadjuvant and adjuvant therapies in prostate cancer. 2010 , 37, 97-104, Table of Contents	8
1051	Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond. 2010 , 7, 17-22	1
1050	Modern immunotherapy for the treatment of prostate cancer. 2010 , 7, 37-42	0
1049	Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. 2010 , 7, 31-35	6
1048	Antiangiogenic agents in the treatment of prostate cancer. 2010 , 7, 9-15	0
1047	New frontiers in therapy for metastatic prostate cancer. 2010 , 7, 1-3	
1046	Bone-targeted therapy in metastatic prostate cancer: osteoclast inhibitors and bone-seeking radiopharmaceuticals. 2010 , 7, 23-29	1
1045	Evolution of Docetaxel-Based Therapy for Metastatic Castrate-Resistant Prostate Cancer. 2010 , 3, 225-230	3
1044	The current and emerging role of immunotherapy in prostate cancer. 2010 , 8, 10-6	9
1043	Molecular genetics of prostate cancer: new prospects for old challenges. 2010 , 24, 1967-2000	659
1042	Handbook of Evidence-Based Radiation Oncology. 2010 ,	32
1041	Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. 2010 , 16, 2906-14	51

1040	Survivin is not induced by novel taxanes. 2010 , 7, 2216-23	3
1039	Metabolic control analysis indicates a change of strategy in the treatment of cancer. 2010 , 10, 626-39	63
1038	Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. 2010 , 71, 496-504	67
1037	Survival comparison between glioblastoma multiforme and other incurable cancers. 2010 , 17, 417-21	112
1036	Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients. 2010 , 64, 363-8	30
1035	Novel targeted therapeutics for metastatic castration-resistant prostate cancer. 2010 , 291, 1-13	62
1034	Molecular and traditional chemotherapy: a united front against prostate cancer. 2010 , 293, 1-14	17
1033	Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer. 2010 , 292, 176-85	20
1032	[Combination of external irradiation and androgen suppression for prostate cancer: facts and questions]. 2010 , 14, 510-4	5
1031	Targeted therapeutic approaches for hormone-refractory prostate cancer. 2010 , 36, 122-30	56
1030	Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a systematic review. 2010 , 36, 501-6	13
1029	The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. 2010 , 46, 517-25	107
1028	Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. 2010 , 46, 2027-35	44
1027	The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. 2010 , 46, 1770-2	65
1026	Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study. 2010 , 28, 21-7	28
1025	Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. 2010 , 28, 152-6	16
1024	Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens. 2010 , 28, 290-5	2
1023	A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer. 2010 , 28, 4937-44	21

1022	Innovations in the systemic therapy of prostate cancer. 2010 , 7, 13-21	19
1021	Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting. 2010 , 40, 201-8	4
1020	Cabazitaxel improves survival in castration-resistant prostate cancer patients with disease progression on docetaxel. 2010 , 7, 542-543	
1019	Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment. 2010 , 62, 148-53	17
1018	Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial. 2010 , 97, 312-7	29
1017	Revisiting the ultimate target of treatment for prostate cancer. 2010 , 375, 1409-10	1
1016	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. 2010 , 376, 1147-54	2311
1015	Cabazitaxel in prostate cancer: stretching a string. 2010 , 376, 1119-20	10
1014	External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. 2010 , 11, 1066-73	646
1013	MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. 2010 , 1, 381-387	106
1012	Alternative and Complementary Therapies for Cancer. 2010 ,	1
1011	From Molecular to Modular Tumor Therapy. 2010 ,	5
1010	Microtubule Targeting Agents. 2010 , 179-194	3
1009	Genomic Evaluation and Management of Prostate Cancer. 2010 , 477-492	
1008	[Chemotherapy with docetaxel in prostate cancer. A case report]. 2010 , 20 Suppl 1, S80-3	
1007	ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. 2010 , 12, 1031-40	46
1006	Sipuleucel-T immunotherapy for castration-resistant prostate cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 411-22	59.2 3838
1005	Contemporary treatment of high-risk localized prostate cancer. 2010 , 10, 1069-76	2

1004	Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients?. 2010 , 27, 689-96	18
1003	A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. 2010 , 183, 2219-26	27
1002	Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. 2010 , 13, 351-61	40
1001	Horizon scanning for novel therapeutics for the treatment of prostate cancer. 2010 , 19, 1487-502	3
1000	Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies. 2010 , 10, 1991-2002	4
999	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v129-33	78
998	Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria. 2010 , 62, 379-89	65
997	Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium. 2010 , 28, 275-9	6
996	Zibotentan for the treatment of castrate-resistant prostate cancer. 2010 , 19, 899-908	19
995	Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. 2011 , 17, 3884-91	97
994	Bone metastasis in prostate cancer: emerging therapeutic strategies. 2011 , 8, 357-68	205
993	Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. 2011 , 12, 2433-9	4
992	Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?. 2011 , 11, 99-108	5
991	Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. 2011 , 14, 192-205	50
990	Sipuleucel-T in metastatic castration-resistant prostate cancer: profile report. 2011 , 25, 255-6	2
989	Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. 2011 , 20, 769-78	22
988	Health-related quality of life and cancer clinical trials. 2011 , 3, 57-71	127
987	Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates. 2011 , 8, 1090-9	48

986	The changing therapeutic landscape of castration-resistant prostate cancer. 2011 , 8, 597-610	118
985	Abiraterone and increased survival in metastatic prostate cancer. <i>New England Journal of Medicine</i> , 2011 , 364, 1995-2005	59.2 3019
984	How Multidisciplinary Teams (MDTs) Work in Practice in the Management of Advanced Prostate Cancer: A Survey of Oncologists and Urologists in the UK. 2011 , 4, 68-77	1
983	The Evolution and Current Paradigm of Chemotherapy for Metastatic Castrate-Resistant Prostate Cancer. 2011 , 4, S2-S8	2
982	Metastatic Castrate-Resistant Prostate Cancer: New Landscape, New Challenges. 2011 , 4, S9-S13	2
981	Cabazitaxel Side Effects: Prevention and Management. 2011 , 4, S21-S27	3
980	Towards a New Era in Care for Metastatic Castrate-Resistant Prostate Cancer. 2011 , 4, S1-S1	
979	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. 2011 , 35, 565-579	11
978	Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. 2011 , 2, 151-9	28
977	Palliative care in urology. 2011 , 91, 429-44, x	3
976	Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. 2011 , 14, 80-9	8
975	Sipuleucel-T: in metastatic castration-resistant prostate cancer. 2011 , 71, 101-8	36
974	Cabazitaxel: a novel microtubule inhibitor. 2011 , 71, 1251-8	34
973	In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. 2011 , 10, 1728-39	93
972	Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. 2011 , 11, 221	44
971	Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. 2011 , 11, 375	24
970	Drug resistance in metastatic castration-resistant prostate cancer. 2011 , 8, 12-23	243
969	A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor. 2011 , 13, 236-41	20

968	Practical Urology: Essential Principles and Practice. 2011 ,	9
967	Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. 2011 , 71, 6019-29	341
966	[Renal vein thrombosis, hydronephrosis and prostate cancer]. 2011 , 92, 247-9	
965	PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. 2011 , 17, 3520-6	409
964	Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. 2011 , 13, 40-8	51
963	Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. 2011 , 13, 783-4	6
962	Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. 2011 , 185, 787-94	84
961	Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. 2011 , 178, 525-36	80
960	The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro. 2011 , 178, 1847-60	22
959	Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature. 2011 , 37, 444-55	33
958	Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients. 2011 , 37, 643-54	7
957	PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NF κ B and PPAR γ 2011 , 55, 202-10	52
956	Vitamin D and cancer: clinical aspects. 2011 , 25, 605-15	25
955	Treatment and prevention of bone complications from prostate cancer. 2011 , 48, 88-95	68
954	The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. 2011 , 313, 84-90	36
953	Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. 2011 , 47, 1328-35	17
952	Management of metastatic castration-resistant prostate cancer after first-line docetaxel. 2011 , 47, 2133-42	12
951	Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. 2011 , 68, 103-5	13

950	Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. 2011 , 69, 296-303	26
949	Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. 2011 , 70, 194-6	10
948	Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. 2011 , 344, 1-24	60
947	Cancer de prostate m̄tastatique r̄sistant ^ la castration : le point de vue de lâncologue m̄dical. 2011 , 35, 378-383	0
946	Prostate cancer overview. 2011 , 27, 241-50	51
945	Living with bodily changes in hormone-refractory prostate cancer. 2011 , 27, 309-16	4
944	Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. 2011 , 38, 1093-102	26
943	Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. 2011 , 77, 682-7	21
942	Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. 2011 , 77, 1088-95	8
941	Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. 2011 , 77, 1172-6	12
940	Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. 2011 , 78, 1131-5	41
939	Epothilones in prostate cancer. 2011 , 29, 358-65	4
938	Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. 2011 , 29, 608-13	12
937	Phase I trial with a combination of docetaxel and ²²³ Rn-lexidronam in patients with castration-resistant metastatic prostate cancer. 2011 , 29, 670-5	20
936	Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. 2011 , 29, 593-601	27
935	Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. 2011 , 29, 676-81	12
934	New and emerging agents for the treatment of castration-resistant prostate cancer. 2011 , 29, S1-8	44
933	Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer. 2011 , 47 Suppl 3, S189-94	3

932	Novel treatments for castration-resistant prostate cancer. 2011 , 47 Suppl 3, S195-9	5
931	Experimental models for the development of new medical treatments in prostate cancer. 2011 , 47 Suppl 3, S200-14	6
930	End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. 2011 , 29, 3695-704	164
929	Prostate cancer and biologics. 2011 , 8, 20-22	
928	PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. 2011 , 41, 29-44	70
927	A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. 2011 , 186, 448-51	54
926	Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. 2011 , 186, 877-81	39
925	A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. 2011 , 186, 882-7	27
924	Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer. 2011 , 78, 968.e7-11	16
923	Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. 2011 , 17, 949-64	46
922	Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade. 2011 , 52, 461-5	9
921	New options for the management of castration-resistant prostate cancer: a case perspective. 2011 , 9 Suppl 3, S13-23; quiz S24	3
920	Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients. 2011 , 34, 155-9	14
919	Docetaxel/Prednisone (D + P): Metastatic Hormone-Refractory Prostate Cancer. 2011 , 46, 489-493	
918	Prostate Cancer Metastasis: Thoughts on Biology and Therapeutics. 456-464	
917	Parallel determination of NeuroD1, chromogranin-A, Ki67 and androgen receptor expression in surgically treated prostate cancers. 2011 , 37, 57-66	12
916	Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer. 2011 , 2, 579-584	15
915	Current treatment strategies for castration-resistant prostate cancer. 2011 , 52, 157-65	19

914	Limited expression of cytochrome p450 17 β -hydroxylase/17,20-lyase in prostate cancer cell lines. 2011 , 52, 494-7	9
913	Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. 2011 , 233	
912	Prognostic Factors for Failure after Prostatectomy. 2011 , 2, 1-19	37
911	Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. 2011 , 4, 79-96	4
910	[Low-dose docetaxel in combination with dexamethasone for hormone-refractory prostate cancer]. 2011 , 102, 23-7	1
909	An update on TroVax for the treatment of progressive castration-resistant prostate cancer. 2011 , 4, 33-41	2
908	Current Options and Future Directions in Castrate Resistant Prostate (CRPC). 2011 ,	
907	Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. 2011 , 2, 59	16
906	HIGH-INTENSITY FOCUSED ULTRASOUND FOR THE TREATMENT OF LOCALIZED AND LOCALLY ADVANCED HORMONE-RESISTANT PROSTATE CANCER: 2,5 YEAR OUTCOME. 2011 ,	
905	Dasatinib: an anti-tumour agent via Src inhibition. 2011 , 12, 563-78	88
904	Contemporary management of metastatic castration-resistant prostate cancer. 2011 , 21, 241-7	7
903	Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2011 , 34, 472-7	19
902	Using self-assembled nanomaterials to inhibit the formation of metastatic cancer stem cell colonies in vitro. 2011 , 20, 127-31	8
901	Novel agents and new therapeutics in castration-resistant prostate cancer. 2011 , 23, 290-6	21
900	C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. 2011 , 36, 192-8	65
899	Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. 2011 , 34, 292-6	63
898	Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. 2011 , 29, 4022-8	177
897	Differences and Similarities of Epothilones. 2011 , 7, 10-36	10

896	New therapeutic strategies for castration-resistant prostate cancer. 2011 , 6, 373-83	2
895	Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A?DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. 2011 , 2, 523-528	21
894	Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer. 2011 , 25, 937-44	14
893	Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab. 2011 , 38, 1137-43	11
892	Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines. 2011 , 38, 1489-500	8
891	Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. 2011 , 5, 117-24	87
890	Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independence. 2011 , 2, 221-228	20
889	Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells. 2011 , 38, 365-74	8
888	Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy. 2010 , 8, 81-7	11
887	Care of the elderly patient with prostate cancer: what's new and what's the same. 2011 , 26, 390-9	
886	Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells. 2011 , 38, 665-76	9
885	Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. 2011 , 107, 234-9	71
884	Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. 2011 , 107, 1488-99	18
883	Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. 2011 , 108, 223-7	6
882	Improved survival prospects for patients with castration-resistant prostate cancer. 2011 , 107, 697-700	5
881	Maximizing outcomes in genitourinary cancers across the treatment continuum. 2011 , 107 Suppl 2, 1-12	1
880	Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. 2011 , 107 Suppl 2, 13-20	27
879	The use of estramustine phosphate in the modern management of advanced prostate cancer. 2011 , 108, 1782-6	30

878	Dynamic prediction of metastases after radical prostatectomy for prostate cancer. 2011 , 108, 1762-8	6
877	Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. 2011 , 107, 1326-7; author reply 1327	1
876	Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial. 2011 , 108, 1825-32	17
875	Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. 2011 , 102, 769-75	16
874	Second-line therapy for castrate-resistant prostate cancer: a literature review. 2011 , 7, 212-23	3
873	Therapeutic cancer vaccines: are we there yet?. 2011 , 239, 27-44	218
872	Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. 2011 , 18, 969-78	9
871	Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. 2011 , 104, 613-9	12
870	A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. 2011 , 104, 620-8	40
869	Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). 2011 , 41, 558-65	160
868	Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum. 2011 , 38, 309-25	20
867	Cancer immunotherapy: sipuleucel-T and beyond. 2011 , 31, 813-28	67
866	A population-based study of prostate cancer chemotherapy. 2011 , 23, 706-8	22
865	A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells. 2011 , 658, 98-107	37
864	Words of wisdom. Re: Testicular spermatozoa have statistically significantly lower DNA damage compared with ejaculated spermatozoa in patients with unsuccessful oral antioxidant treatment. 2011 , 59, 657-8	0
863	Words of wisdom. Re: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. 2011 , 59, 658	4
862	Words of wisdom. Re: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. 2011 , 59, 659	1
861	Words of wisdom. Re: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. 2011 , 59, 659-61	1

- 860 EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. **2011**, 59, 572-83 386
- 859 The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. **2011**, 60, 270-8 39
- 858 New therapies for castration-resistant prostate cancer: efficacy and safety. **2011**, 60, 279-90 111
- 857 Prolonged remission of fulminant castrate-resistant prostate cancer: a case report. **2011**, 9, 133-6
- 856 Ten years of docetaxel-based therapies in prostate adenocarcinoma: a systematic review and meta-analysis of 2244 patients in 12 randomized clinical trials. **2011**, 9, 115-23 10
- 855 Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment. **2011**, 9, 130-2 1
- 854 Immunotherapy for treatment of advanced prostate cancer. **2011**, 12, 10-13
- 853 Cytostatic and cytotoxic drugs. **2011**, 33, 935-962 1
- 852 A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. **2011**, 29, 118-25 19
- 851 [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. **2011**, 35, 565-79 39
- 850 Debating controversies in the management of advanced prostate cancer. **2011**, 2, 39-41
- 849 A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human $\beta(v)$ integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. **2011**, 29, 674-9 24
- 848 Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. **2011**, 29, 1441-8 10
- 847 A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal[®] dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). **2011**, 29, 1465-74 71
- 846 Docetaxel as a vital option for corticosteroid-refractory prostate cancer. **2011**, 43, 1081-7 8
- 845 Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials. **2011**, 137, 1785-90 16
- 844 A phase I study of combined docetaxel and repeated high activity ¹⁸⁶Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). **2011**, 38, 1990-8 27
- 843 Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. **2011**, 60, 197-206 47

842	CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. 2011 , 60, 781-92	20
841	Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer. 2011 , 60, 715-30	36
840	Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?. 2011 , 60, 1181-93	20
839	A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. 2011 , 67, 293-304	20
838	A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. 2011 , 67, 431-8	2
837	Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. 2011 , 67, 783-90	4
836	A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. 2011 , 67, 927-33	20
835	Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. 2011 , 68, 1119-24	22
834	Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need?. 2011 , 28, 519-27	10
833	Role of nonsteroidal anti-inflammatory drug-activated gene-1 in docetaxel-induced cell death of human colorectal cancer cells with different p53 status. 2011 , 34, 323-30	10
832	Dual blockade of PKA and NF- κ B inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. 2011 , 2, 224-38	24
831	Treating prostate cancer in elderly men: how does aging affect the outcome?. 2011 , 12, 263-75	15
830	Sipuleucel-T: Prototype for development of anti-tumor vaccines. 2011 , 13, 112-9	25
829	Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer. 2011 , 13, 92-6	17
828	Current clinical trials in castrate-resistant prostate cancer. 2011 , 12, 173-9	12
827	Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. 2011 , 6, 260	103
826	Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. 2011 , 4, 18	38
825	Metabolic alterations and targeted therapies in prostate cancer. 2011 , 223, 283-94	124

824	Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index. 2011 , 20, 977-83	20
823	Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis. 2011 , 71, 111-24	11
822	Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. 2011 , 71, 326-31	255
821	Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer. 2011 , 71, 385-93	4
820	Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies. 2011 , 71, 550-7	7
819	Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. 2011 , 71, 1158-66	67
818	Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. 2011 , 71, 1264-75	14
817	Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins. 2011 , 71, 1810-7	21
816	Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: role of Golgi apparatus. 2011 , 226, 3035-42	4
815	A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. 2011 , 117, 526-33	62
814	Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial. 2011 , 117, 752-7	12
813	Screening, risk assessment, and the approach to therapy in patients with prostate cancer. 2011 , 117, 1123-35	74
812	Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. 2011 , 117, 1172-82	20
811	Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. 2011 , 117, 2077-85	115
810	Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. 2011 , 117, 2419-25	11
809	The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. 2011 , 117, 3963-71	30
808	Toward predictors of survival in castration-resistant prostate cancer. 2011 , 117, 3882-4	2
807	BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. 2011 , 128, 1946-54	67

806	Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. 2011 , 128, 2182-91	69
805	Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. 2011 , 112, 2125-37	19
804	Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. 2011 , 32, 2662-72	68
803	Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. 2011 , 29, 2574-81	55
802	Castration-resistant prostate cancer: targeted therapies and individualized treatment. 2011 , 16, 264-75	23
801	Prostate-specific antigen testing across the spectrum of prostate cancer. 2011 , 5, 515-26	21
800	Adjuvant medical therapy for prostate cancer. 2011 , 12, 73-84	7
799	The unfolding treatment landscape for men with castration-resistant prostate cancer. 2011 , 1, 1533-1544	1
798	Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. 2011 , 3, 27-31	9
797	New therapies for castrate-resistant prostate cancer. 2011 , 12, 2069-74	5
796	Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. 2011 , 10, 141-50	19
795	Expanding treatment options for metastatic prostate cancer. <i>New England Journal of Medicine</i> , 2011 , 364, 2055-8	59.2 76
794	Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer. 2011 , 8, 515-6	5
793	[Castration resistant prostate cancer 2011]. 2011 , 42, 95-102	1
792	Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. 2011 , 29, 2191-8	182
791	Cabazitaxel for the treatment of castration-resistant prostate cancer. 2011 , 7, 15-24	12
790	Targeting continued androgen receptor signaling in prostate cancer. 2011 , 17, 3876-83	136
789	Recent advances in second-line treatment of castration-resistant prostate cancer. 2011 , 5, 199-205	2

788	Malignant extradural spinal cord compression in men with prostate cancer. 2011 , 5, 206-10	5
787	Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. 2011 , 22, 2476-2481	77
786	Pathways of chemotherapy resistance in castration-resistant prostate cancer. 2011 , 18, R103-23	69
785	Novel therapies for metastatic castrate-resistant prostate cancer. 2011 , 103, 1665-75	105
784	The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. 2011 , 20, 1677-84	49
783	Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. 2011 , 9, 1755-66	52
782	Clinically relevant anticancer polymer Paclitaxel therapeutics. 2010 , 3, 17-42	33
781	The epothilones: new therapeutic agents for castration-resistant prostate cancer. 2011 , 16, 1349-58	13
780	Broadening horizons in medical management of prostate cancer. 2011 , 50 Suppl 1, 141-7	18
779	Management of advanced prostate cancer--new drugs. 2011 , 50 Suppl 1, 137-40	0
778	Sipuleucel-T: immunotherapy for advanced prostate cancer. 2011 , 3, 49-60	4
777	Abiraterone acetate, an inhibitor of adrenal androgen synthesis in "hormone refractory prostate cancer". 2011 , 32, 43-5	1
776	A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy. 2011 , 1, 12-7	
775	Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?. 2011 , 5, 325-32	2
774	Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. 2011 , 5, 163-9	8
773	Emerging novel therapies in the treatment of castrate-resistant prostate cancer. 2011 , 5, 120-33	13
772	Overcoming chemotherapy resistance in prostate cancer. 2011 , 17, 3892-902	53
771	Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. 2011 , 17, 5765-73	110

770	Castration-resistant prostate cancer: targeted therapies. 2011 , 57, 115-27	12
769	Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer. 2011 , 87, 263-9	14
768	Integrating pain metrics into oncology clinical trials. 2011 , 17, 6646-50	14
767	Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer. 2011 , 41, 253-9	15
766	Chemotherapy-based treatment for castration-resistant prostate cancer. 2011 , 29, 3686-94	68
765	Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. 2011 , 10, 720-31	45
764	New strategies for medical management of castration-resistant prostate cancer. 2011 , 80, 1-11	22
763	Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. 2011 , 12, 119-24	16
762	The role of RANK-ligand inhibition in cancer: the story of denosumab. 2011 , 16, 136-45	95
761	Emerging therapies to prevent skeletal morbidity in men with prostate cancer. 2011 , 29, 3705-14	61
760	Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. 2011 , 17, 3867-75	48
759	Prostate cancer: evolution or revolution?. 2011 , 29, 3595-8	8
758	Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. 2011 , 29, 2543-9	52
757	Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. 2011 , 105, 1640-5	45
756	Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. 2011 , 8, 569-678	37
755	Cabazitaxel for the treatment of prostate cancer. 2011 , 12, 977-82	6
754	TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. 2011 , 7, 497-506	63
753	Patupilone in cancer treatment. 2011 , 20, 107-17	24

752	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. 2011 , 10, 743-53	15
751	Metastasizing, Luciferase Transduced MAT-Lu Rat Prostate Cancer Models: Follow up of Bolus and Metronomic Therapy with Doxorubicin as Model Drug. 2011 , 3, 2679-95	4
750	123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. 2011 , 52, 1087-93	63
749	Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. 2011 , 2011, 258689	14
748	Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer. 2011 , 3, 3449-60	2
747	Reply to M. Fink. 2011 , 29, 4337-4338	
746	Novel approaches and future directions in castration-resistant prostate cancer. 2011 , 22, 1948-1957	15
745	Effect of Vitamin D Supplementation in Prostate Cancer: A Systematic Review of Randomized Control Trials. 2018 , 88, 100-112	7
744	A good molecular target for prostate cancer chemotherapy. 2011 , 13, 207	1
743	Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer. 2011 , 13, 366-8	7
742	Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. 2011 , 13, 683-9	4
741	Overexpression of ETS-1 is associated with malignant biological features of prostate cancer. 2012 , 14, 860-3	10
740	An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. 2013 , 15, 231-5	51
739	The effectiveness of the TAX 327 nomogram in predicting overall survival in Chinese patients with metastatic castration-resistant prostate cancer. 2013 , 15, 679-84	2
738	Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison. 2013 , 15, 773-9	8
737	Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers. 2020 , 11, 2540	15
736	Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. 2007 , 18, 949-54	8
735	Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy. 2011 , 34, 140-4	13

734	Capitalizing on Competition: An Evolutionary Model of Competitive Release in Metastatic Castration Resistant Prostate Cancer Treatment.	1
733	Age-Sex based estimates of risk of death from COVID Infection in Adult Cancer Patients.	4
732	Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.	4
731	Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review. 2012 , 2012,	6
730	Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. 2020 , 19, 1708-1718	18
729	Multiparametric liquid biopsy analysis in metastatic prostate cancer. 2019 , 4,	33
728	Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. 2020 , 130, 3287-3298 ¹³	
727	The evolving biology and treatment of prostate cancer. 2007 , 117, 2351-61	101
726	Neuron-specific enolase has potential value as a biomarker for [F]FDG/[Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients. 2020 , 10, 52	8
725	Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer. 2020 , 16, e201-e210	7
724	Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway. 2017 , 23, 5793-5802	21
723	Establishment of a syngeneic orthotopic model of prostate cancer in immunocompetent rats. 2015 , 28, 21-6	3
722	Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: A study of 1358 patients. 2020 , 8, 54-67	5
721	Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. 2008 , 6, 2853-68	2289
720	Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems. 2010 , 5, e8864	27
719	In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. 2012 , 7, e40716	61
718	Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel. 2012 , 7, e48186	23
717	Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. 2012 , 7, e51189	28

7 ¹⁶	In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression. 2013 , 8, e53795	20
7 ¹⁵	The role of hypoxia-inducible factor 1 β in determining the properties of castrate-resistant prostate cancers. 2013 , 8, e54251	56
7 ¹⁴	Riccardin D Exerts Its Antitumor Activity by Inducing DNA Damage in PC-3 Prostate Cancer Cells In Vitro and In Vivo. 2013 , 8, e74387	6
7 ¹³	A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice. 2013 , 8, e74924	69
7 ¹²	Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study. 2014 , 9, e95310	3
7 ¹¹	Towards engineering hormone-binding globulins as drug delivery agents. 2014 , 9, e113402	11
7 ¹⁰	A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer. 2015 , 10, e0117002	13
7 ⁰⁹	Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice. 2016 , 11, e0147173	14
7 ⁰⁸	A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer. 2016 , 11, e0157548	4
7 ⁰⁷	Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. 2015 , 108, 224-8	11
7 ⁰⁶	Progress in the treatment of advanced prostate cancer. 2014 , 117-31	29
7 ⁰⁵	Geriatric oncology and clinical trials. 2015 , e127-31	7
7 ⁰⁴	Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer. 2019 , 26, 131-140	13
7 ⁰³	p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer. 2020 , 27, 187-198	8
7 ⁰²	Impact of the COVID-19 Pandemic on the Urologist's clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period. 2020 , 46, 501-510	36
7 ⁰¹	Mini review on emerging methods of preparation of liposome and its application as Liposome drug delivery systems. 2017 , 3, 005-021	5
7 ⁰⁰	SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES. 2018 , 14, 120-127	2
6 ⁹⁹	NEW TREATMENT STANDARD FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. 2018 , 14, 68-77	1

698	Second line chemotherapy in patients with castration-refractory prostate cancer. From clinical studies to practice. 2019 , 15, 84-91	1
697	The National Registry of treatment regimens in patients with metastatic castration-resistant prostate cancer in the Russian Federation. 2019 , 15, 78-88	2
696	FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer. 2020 , 12, 6352-6369	9
695	Versican is a potential therapeutic target in docetaxel-resistant prostate cancer. 2015 , 2, 193-204	8
694	Mcl-1 protects prostate cancer cells from cell death mediated by chemotherapy-induced DNA damage. 2015 , 2, 703-15	21
693	Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. 2016 , 7, 64447-64470	95
692	Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth. 2016 , 7, 68072-68085	11
691	Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer. 2016 , 7, 70388-70403	12
690	Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction. 2016 , 7, 68650-68661	28
689	Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1 β and sphingosine kinase 1. 2016 , 7, 80943-80956	26
688	Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer. 2013 , 4, 2225-36	55
687	Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts. 2017 , 8, 9134-9143	6
686	Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer. 2016 , 7, 83735-83743	15
685	Epigenetic therapy in urologic cancers: an update on clinical trials. 2017 , 8, 12484-12500	27
684	Glycogen synthase kinase-3 β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth. 2014 , 5, 8986-94	36
683	Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. 2014 , 5, 667-78	26
682	CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4. 2017 , 8, 65143-65151	29
681	Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. 2017 , 8, 56698-56713	76

680	Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis. 2017, 8, 47849-47860	40
679	The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. 2017, 8, 55374-55383	19
678	Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness. 2014, 5, 7357-67	17
677	The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. 2014, 5, 6896-908	24
676	Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study. 2017, 8, 110774-110784	6
675	A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. 2018, 9, 8155-8164	8
674	Analysis of hematological parameters as prognostic markers for toxicity and survival of Radium treatment. 2018, 9, 16197-16204	5
673	Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. 2018, 9, 25586-25596	48
672	Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition. 2014, 5, 11399-412	54
671	RNA sequencing reveals upregulation of a transcriptomic program associated with stemness in metastatic prostate cancer cells selected for taxane resistance. 2018, 9, 30363-30384	10
670	PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. 2014, 5, 12043-56	24
669	Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme. 2019, 10, 4161-4168	5
668	A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting. 2019, 10, 5082-5091	4
667	Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer. 2015, 6, 3887-903	23
666	Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. 2015, 6, 1900-19	65
665	Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer. 2015, 6, 13803-21	28
664	Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase. 2015, 6, 10030-44	33
663	Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. 2015, 6, 15652-61	42

- 662 Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. **2015**, 6, 23358-71 67
- 661 Exosomes confer pro-survival signals to alter the phenotype of prostate cells in their surrounding environment. **2016**, 7, 14639-58 59
- 660 The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer. **2012**, 3, 1483-4 11
- 659 Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. **2016**, 7, 69397-69411 13
- 658 Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative. **2016**, 7, 27489-98 8
- 657 Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer. **2016**, 7, 28891-902 15
- 656 Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. **2016**, 7, 35818-35831 15
- 655 Medical management of metastatic prostate cancer. **2018**, 41, 154-159 8
- 654 Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel. **2020**, 3, 636-646 3
- 653 The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies. **2016**, 5, S1107-S1110 14
- 652 Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. **2011**, 3, 233-45 23
- 651 Magnetic nanoparticles of Fe₃O₄ enhance docetaxel-induced prostate cancer cell death. **2013**, 8, 3151-60 19
- 650 Gold Nanoparticles; Potential Nanotheranostic Agent in Breast Cancer: A Comprehensive Review with Systematic Search Strategy. **2020**, 21, 579-598 5
- 649 Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions. **2019**, 19, 368-381 5
- 648 Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives. **2019**, 19, 57-73 21
- 647 A Systematic Review and Meta-Analysis about the Effect of Bisphosphonates on the Risk of Skeletal-Related Event in Men with Prostate Cancer. **2020**, 20, 1604-1612 2
- 646 Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial. **2018**, 7, e11191 6
- 645 Castrate-resistant prostate cancer: the right targets and combinations. **2008**, 5, 57-61 1

644	Chemotherapy in the elderly: are their needs being met?. 2009 , 6, 893-902	2
643	Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer. 2017 , 15, 59-65	2
642	Multimodal treatment for high-risk locally-advanced prostate cancer following radical prostatectomy and extended lymphadenectomy. 2019 , 71, 508-515	4
641	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. 2016 , 20, 1-288	20
640	Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. 2020 , 14, 1036	1
639	Imaging for Metastasis in Prostate Cancer: A Review of the Literature. 2020 , 10, 55	22
638	Cardiovascular Complications of Prostate Cancer Treatment. 2020 , 11, 555475	4
637	Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer. 2015 , 7, 2290-308	37
636	Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain. 2018 , 6, 1-14	1
635	New multidisciplinary prostate bone metastases clinic: first of its kind in Canada. 2007 , 14, 9-12	12
634	Preventing bone complications in advanced prostate cancer. 2010 , 17 Suppl 2, S65-71	7
633	MicroRNA-122 regulates docetaxel resistance of prostate cancer cells by regulating. 2020 , 20, 247	3
632	Assessment of biochemical recurrence of prostate cancer (Review). 2019 , 55, 1194-1212	8
631	□Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer. 2020 , 19, 2306-2316	2
630	Downregulation of lysine-specific demethylase 1 enhances the sensitivity of hormone-sensitive prostate cancer cells to androgen deprivation therapy. 2021 , 21, 93	2
629	Current clinical challenges in prostate cancer. 2013 , 2, 122-36	22
628	Novel non-AR therapeutic targets in castrate resistant prostate cancer. 2013 , 2, 265-77	4
627	Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. 2015 , 4, 355-64	13

626	Mechanisms of resistance in castration-resistant prostate cancer (CRPC). 2015 , 4, 365-80	194
625	Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. 2016 , 32, 257-261	7
624	Chemotherapy options in castration-resistant prostate cancer. 2016 , 32, 262-270	16
623	Immunotherapy in metastatic prostate cancer. 2016 , 32, 271-276	5
622	Update in palliative management of hormone refractory cancer of prostate. 2007 , 23, 43-50	1
621	Evolving perspectives of the role of novel agents in androgen-independent prostate cancer. 2008 , 24, 303-8	1
620	The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. 2012 , 28, 9-14	15
619	Saudi Oncology Society clinical management guidelines for prostate cancer. 2011 , 3 Suppl, S10-6	3
618	Chemotherapy and its evolving role in the management of advanced prostate cancer. 2014 , 16, 334-40	14
617	Treatment sequencing in metastatic castrate-resistant prostate cancer. 2014 , 16, 426-31	36
616	New developments in the treatment of castration resistant prostate cancer. 2014 , 16, 555-60	4
615	Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. 2014 , 16, 387-400	31
614	Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. 2016 , 18, 580-5	29
613	Prostate Cancer for the Internist. 2015 , 7, 429-35	13
612	PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. 2018 , 20, 173-177	4
611	Impact of taxanes on androgen receptor signaling. 2019 , 21, 249-252	5
610	External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer. 2018 , 20, 184-188	5
609	The path forward in prostate cancer therapeutics. 2018 , 20, 213-214	2

608	Role of chemotherapy in prostate cancer. 2018 , 20, 221-229	43
607	Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study. 2018 , 20, 545-550	5
606	Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer. 2017 ,	5
605	Experience with using fosfestrol for treating metastatic castrate-resistant prostate cancer in resource-limited setting. 2019 , 40, 79-84	1
604	Clinicoradiological Profile and Treatment Outcomes in Prostate Cancer at a Tertiary Care Cancer Center in India. 2020 , 41, 187-192	1
603	Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer. 2020 , 35, 299-304	8
602	Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting. 2020 , 61, 19-27	3
601	Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. 2010 , 42, 12-7	19
600	Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05). 2018 , 50, 1252-1259	20
599	Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?. 2012 , 8, 528-32	6
598	Hormonal therapy and chemotherapy for advanced prostate cancer. 2015 , 58, 30	3
597	How Precisely Can Prostate Cancer Be Managed?. 2016 , 20, S120-130	8
596	Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. 2015 , 6, 64-72	5
595	Is there still a place for docetaxel rechallenge in prostate cancer?. 2015 , 6, 99-103	15
594	Guidelines for the management of castrate-resistant prostate cancer. 2010 , 4, 380-4	81
593	Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. 2012 , 6, 465-70	24
592	Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice. 2013 , 7, S11-7	10
591	Optimal management of patients receiving cabazitaxel-based chemotherapy. 2013 , 7, S18-24	5

590	Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. 2016 , 10, 102-9	11
589	Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy. 2020 , 38, 226-235	3
588	Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review. 2020 , 38, 151-163	3
587	End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review. 2014 , 4, 123-32	1
586	[Clinical study of long-term docetaxel based chemotherapy treatment for patients with castration-resistant prostate cancer]. 2014 , 105, 172-7	4
585	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 2019 , 17, 479-505	562
584	siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells. 2012 , 13, 2485-9	22
583	Predictive factors for neutropenia after docetaxel-based systemic chemotherapy in Korean patients with castration-resistant prostate cancer. 2014 , 15, 3443-6	6
582	Inhibition of Transient Receptor Potential Melastain 7 Enhances Apoptosis Induced by TRAIL in PC-3 cells. 2015 , 16, 4469-75	12
581	Repurposing FDA-approved phytochemicals, natural products, antivirals and cell protectives against SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase. 2020 , 8, e10480	11
580	ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. 2013 , 1, e144	37
579	The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells. 2016 , 4, e2168	7
578	Risk of Death from Prostate Cancer with and without Definitive Local Therapy when Gleason Pattern 5 is Present: A Surveillance, Epidemiology, and End Results Analysis. 2017 , 9, e1453	3
577	Diethylstilbestrol in the Treatment of Castration-resistant Prostate Cancer: A Lower-middle-income Country Experience. 2019 , 11, e4470	2
576	Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer. 2021 , 1329, 295-323	0
575	Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. 2021 , 35, 3509-3519	1
574	Prostate Cancer: Advanced and Metastatic Disease. 2021 , 805-821	
573	Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?. 2021 ,	

572 Study protocol for a comparative effectiveness evaluation of abiraterone acetate against enzalutamide: a longitudinal study based on Swedish administrative registers. **2021**, 11, e052610

571 Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. **2021**, 39, 1464-1478.e8 12

570 Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort.. **2022**, 3, 173-183 1

569 Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer. **2021**, 82, 182 1

568 The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. **2021**, 1

567 Docetaxel-based therapy for prostate cancer. **2005**, 1, 231-240

566 Genitourinary Oncology. **2006**, 123-130

565 Horizons for Cancer Chemotherapy (and Nonchemotherapy). **2006**, 445-457

564 Other Novel Therapies. **2006**, 281-289

563 Bone-Directed Therapy in Prostate Cancer: Rationale and Novel Approaches. **2006**, 223-236

562 Molecular Imaging, Clinical Trial Design, and the Development of Emerging Therapies for Metastatic Prostate Cancer. **2006**, 291-313

561 Gene Therapy and Novel Clinical Trial Design. **2006**, 103-125

560 Angiogenesis Inhibitors in Prostate Cancer. **2006**, 127-141

559 Malignome des Urogenitaltrakts. **2007**, 691-744

558 Chemotherapy for hormone-resistant prostate cancer: Where are we today?. **2007**, 23, 55-60

557 Research Highlights. **2008**, 5, 19-22

556 Hormone-Refractory Prostate Cancer: A Rational Approach to Chemotherapy. **2008**, 536-543

555 . **2008**, 120, 207-213

- 554 Antisense Oligonucleotides and siRNA as Specific Inhibitors of Gene Expression: Mechanisms of Action and Therapeutic Potential. **2008**, 337-362
- 553 Frontiers of cancer care in Asia-Pacific region: cancer care in Australia. **2008**, 4, e30 2
- 552 Hormonal and chemotherapeutic options in advanced prostate cancer. **2008**, 4, 455-462
- 551 PROSTATE CANCER. **2009**, 951-957 1
- 550 Prostate Cancer. **2009**, 898-912
- 549 Developments in the Management of Genitourinary Malignancies: Prostate Cancer and Renal Cell Carcinoma. **2009**, 533-544
- 548 Prostate Cancer. **2009**, 578-584
- 547 Genitourinary Complications in Palliative Oncology. **2009**, 1276-1281
- 546 Therapeutic Approaches to Metastatic Bone Cancer II: Targeted and Non-targeted Systemic Agents. **2010**, 219-227
- 545 Prostate Cancer. **2010**, 33-47
- 544 Thalidomide and Analogs. **2010**, 215-223
- 543 Platinum Agents in Prostate Cancer. **2010**, 153-161
- 542 Prostate Cancer. **2010**, 637-640.e1
- 541 [Scleroderma-like skin sclerosis induced by docetaxel chemotherapy for hormone refractory prostate cancer: a case report]. **2010**, 101, 726-9 1
- 540 Bone Metastases of Prostatic Cancer: Pathophysiology, Clinical Complications, Actual Treatment and Future Directions. **2010**, 449-456
- 539 Urogenitale Tumoren. **2010**, 841-861
- 538 What's New in Hormone-refractory Prostate Cancer Treatment. **2010**, 53, 126
- 537 Radiopharmaceuticals. **2010**, 255-266 1

536 Cancer Immunology, Immunotherapeutics, and Vaccine Approaches. **2010**, 305-319

535 Systems Biology: A Therapeutic Target for Tumor Therapy. **2010**, 265-285

534 Modular Therapy Approach in Metastatic Castration-Resistant Prostate Cancer. **2010**, 367-377

1

533 [Prognostic factors for estrogen therapy of relapsed prostate cancer after maximal androgen blockade (MAB)]. **2010**, 101, 597-602

1

532 GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX. **2010**, 329-342

531 Docetaxel. **2010**, 133-146

1

530 Prostate Cancer. **2010**, 431-477

529 Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer. **2010**, 163-177

528 Mining Natural Product-Derived Molecules Against Cancer Targets: The Case of the Androgen Receptor in Prostate Cancer. **2010**, 671-692

527 FDA Approval of Prostate Cancer Treatments. **2010**, 399-405

526 Challenges for the Development of New Agents in Prostate Cancer. **2010**, 389-397

525 Men's Health Topics. **2010**, 752-769

524 Chemoprevention of Prostate Cancer. **2010**, 69, 75-81

523 Surgical Treatment Options for Locally Advanced Prostate Cancer. 267-278

522 Microenvironment Factors Influencing Skeletal Metastases. 135-160

521 Prise en charge thérapeutique des cancers de prostate. **2011**, 427-456

520 Chemotherapeutic Agents for Urologic Oncology. **2011**, 175-186

0

519 Inhibitory effect of docetaxel conjugate PLA-PEG block copolymers on proliferation of prostate cancer cell line PC-3. **2011**, 31, 337-338

- 518 Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer. **2011**, 13, 657-8
- 517 Autologous cellular immunotherapy in late-stage prostate cancer: The development history of Sipuleucel-T (PROVENGE®). **2011**, 44-55 1
- 516 Design, development, and translation of poxvirus-based vaccines for cancer. **2011**, 56-77 1
- 515 Topoisomerase II Inhibitors: Current Use and Prospects. **2012**, 279-307 1
- 514 Antiangiogenesis agents. **2011**, 22-31
- 513 Overview of disease pathways and drug targets. **2011**, 6-21
- 512 Rational Design of DNA Anticancer Agent That Targets Signal Transducer and Activator of Transcription 3 (Stat3) for Cancer Therapy. **2012**, 167-190
- 511 Androgen Receptor Pathway in Prostate Cancer: Old Target and New Drugs. **2012**, 213-223
- 510 Anti-angiogenic therapy for prostate cancer: rationale and ongoing trials. **2011**, 1, 1651-1661
- 509 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61
- 508 Management of Newly Diagnosed Metastatic Disease. **2012**, 361-378
- 507 Resistance to Chemical Castration: Second-Line Hormonal Treatment. **2012**, 251-259
- 506 Targeted Therapies and Vaccination. **2012**, 261-275
- 505 Examination on the Effect of Docetaxel Dilution Concentration on the Hypersensitivity Revelation Rate. **2012**, 38, 547-558
- 504 Clinical State of the Rising PSA Value after Definitive Local Therapy. **2012**, 2921-2933.e3
- 503 Prostate Cancer. **2012**, 1037-1097 0
- 502 Prostate Cancer. **2012**, e51-1-e51-85
- 501 Combination of Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced and Localized Prostate Cancer. **2012**, 157-171

- 500 Current Management of Castration-Resistant Prostate Cancer (CRPC). **2012**, 401-411
- 499 Management of Prostate Cancer: EAU Guidelines on Screening, Diagnosis and Treatment. **2012**, 299-326
- 498 First-line docetaxel chemotherapy for castrate-resistant prostate cancer.
- 497 Experimental therapeutics in prostate cancer: where are we now and where do we need to go. **2012**, 14, 421-2
- 496 New developments in prostate cancer therapy. **2012**, 309-13
- 495 Prostate Cancer: Predictive Markers in Clinical Development. **2013**, 69-103
- 494 Clinical Management of Elderly Patientsâ€”Metastatic Prostate Cancer: Other Treatments and Supportive Care. **2013**, 203-216
- 493 Clinical Management of Elderly Patients with Metastatic Prostate Cancer Chemotherapy. **2013**, 179-201
- 492 Management of Bone Metastases. **2013**, 1055-1063
- 491 Prostate Carcinoma Surveillance Counterpoint: Japan. **2013**, 423-425
- 490 Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer. **2013**, 901-923
- 489 Identification, characterization and targeting of Docetaxel-resistant prostate cancer cells. **2013**, 15, 83-4
- 488 Nursing Issues in Prostate Cancer. **2013**, 1081-1090
- 487 Future Directions in Metastatic Castration Resistant Prostate Cancer (mCRPC): Clinical Rationale and Use of New-Generation Hormonal Therapies. **2013**, 04, 698-703
- 486 Metastatic Dissemination. **2013**, 111-125
- 485 Bone Therapy. **2013**, 643-652
- 484 [Salvage therapy for castration-refractory prostate cancer resistant to docetaxel]. **2013**, 104, 681-7
- 483 Resistance to Castration â€”Resistance to Drugs. **2013**, 127-142

- 482 Redirecting and Modulating Rationalizations of Tumor-Immanent Normative Functions in Castration-Resistant Prostate Cancer. **2013**, 47-66
- 481 Chemotherapy in Older Adults with Cancer. 205-220
- 480 Chemotherapy for prostate cancer: Clinical practice in Canada. **2013**, 7, S5-S10 4
- 479 Metastatic castration-resistant prostate cancer: The emerging continuum of care. **2013**, 7, S3 1
- 478 First-line docetaxel chemotherapy for castrate-resistant prostate cancer.
- 477 Adverse Side Effects Associated with the Use of Low-Dose Metronomic Chemotherapy. **2014**, 263-279
- 476 Defining Clinical Endpoints in Castration-Resistant Prostate Cancer. **2014**, 187-199
- 475 Prostate Cancer in Older Adults. **2014**, 273-288
- 474 Prostate Cancer. **2014**, 201-205
- 473 Prostatakarzinom. **2014**, 513-676
- 472 Introduction. **2014**, 167-176
- 471 Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development. **2014**, 321-327
- 470 Prostate Cancer Vaccines Generated with the Disruptive RNAActive[®] Technology Follow the Path Paved by Sipuleucel-T and Prostavac-VF. **2014**, 155-169
- 469 Management of Patients with Prostate Cancer. **2014**, 17-47
- 468 Cytotoxic Chemotherapy (Taxanes and Taxane Combinations). **2014**, 107-119
- 467 Co-targeting Adaptive Survival Pathways. **2014**, 233-248
- 466 Prostate Cancer. **2014**, 657-672
- 465 Strategies Addressing Quality of Life: Management of Patient-Reported Outcomes and Symptoms. **2014**, 307-320

- 464 New Medical Strategies: The Role of Oncologist in an MDT. **2014**, 119-142 1
- 463 Evolution of Clinical States and the Castration Resistant Clinical Paradigm. **2014**, 9-29
- 462 Geriatric considerations in the treatment of advanced prostate cancer. **2014**, 6, 33 3
- 461 Hypertrophie bñgine et cancer de la prostate. **2014**, 19, 28-32
- 460 Liver Metastases from Prostate Cancer. **2015**, 183-206
- 459 Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancer.
- 458 Castrate Resistant Prostate Cancer: Systemic Chemotherapy and a System Problem. **2015**, 835-845
- 457 Prostate Cancer. **2015**, 519-554
- 456 Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer. **2015**, 17, 936-8; discussion 938 1
- 455 Prostatakarzinom: palliative Therapie. **2015**, 1-29 0
- 454 Comparative effectiveness research in urologic cancers. **2015**, 164, 221-35
- 453 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79
- 452 Prostate. 308-326
- 451 Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. **2016**, 8, 123-30 2
- 450 Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. **2016**, 1-41
- 449 Prostate Cancer in the Elderly. **2016**, 63-72
- 448 Cabazitaxel for the Treatment of Prostate Cancer. **2016**, 187-214
- 447 Rapid bench to bed in management of metastatic prostate cancer. **2016**, 32, 255-256

446 Prostatakarzinom: Palliative Therapie. **2016**, 1363-1383

445 Switching of GnRH Agent from Agonist to Antagonist in Patients with Castration-Resistant Prostate Cancer. **2016**, 06, 190-198

444 How to Design Clinical Trials?. **2016**, 79-93

1

443 Sequencing Therapies in Metastatic Castration-Resistant Prostate Cancer. **2016**, 215-230

442 Docetaxel in Advanced and Castration Resistant Prostate Cancer. **2016**, 77-92

441 Anti-metastatic Effect of Garlic Hexane Extract on Lung Metastasis Induced by Melanoma B16F10 Cells in Mice. **2016**, 26, 259-264

440 Assessing the utility of cabazitaxel in mCRPC. **2016**, 10, 111-2

439 Abiraterone: A Review of its Pharmacokinetic, Pharmacodynamic Profile and Clinical Efficacy. **2016**, 3,

438 Modeling and Analysis of Hormone and Mitogenic Signal Integration in Prostate Cancer.

437 Immunotherapy for prostate cancer. **2016**, 17, 159-166

436 Chemotherapy. **2017**, 121-133

435 Approaches for Assessment of Response of Bone Metastases to Therapies. **2017**, 223-249

434 A community-based collaboration to build prediction models for short-term discontinuation of docetaxel in metastatic castration-resistant prostate cancer.

433 Combinations of Hormonal Therapy and Chemotherapy. **2017**, 135-146

432 Bone-Seeking Radionuclide for Therapy. **2017**, 193-207

431 Chapter 6 Plumbagin and Prostate Cancer Therapy. **2016**, 125-144

430 Chemotherapy and Androgen Receptor-Directed Treatment of Castration Resistant Metastatic Prostate Cancer. **2017**, 327-342

429 Role of Chemohormonal Therapy in Management of Patients with Metastatic Hormone Sensitive Prostate Cancer. **2017**, 08, 1149-1159

428 Combination of Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced and Localized Prostate Cancer. **2017**, 217-230

427 Chimiothérapie. **2017**, 159-171

426 Castration Resistant Prostate Cancer Research of Individualized Drug Therapy. **2017**, 07, 123-129

425 Prostaatkanker en de rol van de huisarts. **2017**, 167-186

424 Molecular Pathogenesis of Prostate Cancer. **2017**, 171-189

423 Drug therapy methods in patients with metastatic castration-resistant prostate cancer: Role of somatostatin analogues. **2017**, 6, 76

422 Prostate. 333-342

421 Korean Treatment Guidelines for Metastatic Prostate Cancer Developed by the Korean Association for Clinical Oncology. **2017**, 92, 124-141

420 Prostate Cancer. **2017**,

419 Chemotherapeutic dose scheduling based on tumor growth rates: the case for low dose metronomic high entropy therapies. o

418 Prostatakarzinom beim alten und geriatrischen Patienten. **2018**, 1-8

417 Epidemiology and Etiology. **2018**, 13-26

416 Multimodale Therapie des Prostatakarzinoms. **2018**, 11-30

415 Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer. **2018**, 13, 85-90 1

414 Resection of Metastatic Cancer in Castration-Resistant Patients. **2018**, 185-195

413 Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. **2018**, 1-14

412 Side Effects of Medical Cancer Therapy in Genitourinary Malignancies. **2018**, 179-212

411 Metastatic (Advanced) Prostate Cancer Resistant to Castration: The Time before Resistance Development and Therapeutic Measures Undertaken in Cote d'Ivoire. **2018**, 09, 955-961

- 410 Prostatakarzinom beim alten und geriatrischen Patienten. **2018**, 473-480
- 409 Prediction of Optimal Number of Cycles in Docetaxel Regimen for Patients with mCRPC. **2018**, 345-355
- 408 MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
- 407 Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial (Preprint).
- 406 The role of taxanes in prostate cancer: literature review. **2018**, 14, 130-141
- 405 [Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]. **2018**, 107, 1043-1051
- 404 Is age the limitation of metastatic treatment prostate cancer?. **2018**, 12, 224-230
- 403 AICAR induces apoptosis and inhibits migration of prostate cancer cells through an AMPK/mTOR-dependent pathway.
- 402 Precision Medicine in Castration-Resistant Prostate Cancer. **2018**, 16, 97-102
- 401 Incidence of skeletal-related events in advanced and metastatic prostate cancer patients treated with androgen deprivation therapy in a low- and middle-income country. **2019**, 8, 60
- 400 Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. **2019**, e.1-e.39
- 399 Principles of Chemotherapy in Older Adults. **2019**, 1-20
- 398 Prostate Cancer. **2019**, 583-623
- 397 Radionuclide therapy with radium-223 chloride. A few strokes to the patient's portrait. **2019**, 14, 87-94
- 396 Treatment Sequencing of Abiraterone Acetate plus Prednisone and Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. **2019**, 15, 1
- 395 Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. **2019**, 241-253
- 394 CASTRATION-RESISTANT PROSTATE CANCER: NEW PERSPECTIVES IN PHARMACOLOGICAL TREATMENT. **2019**, 25, 49-58 1
- 393 Nanoparticles as theranostic vehicles in prostate cancer. **2019**, 7, S29 0

- 392 The Treatment of Metastatic and Castration-Resistant Prostate Cancer Patients in Korea. **2019**, 17, 48-59
- 391 The role of ARTAs in treating metastatic castration-resistant prostate cancer. **2019**, 20, 62-65
- 390 Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?. **2021**, 28, 83-87 0
- 389 Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety. **2019**, 146-154
- 388 Radium-223 systemic alpha-radiotherapy: targeted treatment of castration-resistant prostate cancer with bone metastases. **2019**, 15, 134-142
- 387 New treatment options in hormone-sensitive prostate cancer. **2019**, 13, 150-156
- 386  **2019**, 83-85
- 385 Enzalutamide in treatment of the metastatic castrate resistant prostate cancer. **2019**, 13, 157-160
- 384 Chemotherapy of Prostatic Adenocarcinoma : State of the Art 2019. 6,
- 383 New possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancer. **2019**, 15, 89-101
- 382 Possibilities of treatment of patients with castrationrefractory prostate cancer using enzalutamide. **2019**, 176-180
- 381 Systemic Therapies for Patients with Metastatic Spinal Disease. **2020**, 513-522
- 380 Update of the Andalusian Association of Urology protocol for the management of metastatic castration-resistant prostate cancer. **2020**, 44, 125-130
- 379 Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients Who Cannot Receive Cytotoxic Chemotherapy. **2020**, 18, 140-146
- 378 Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?. **2021**, 27, 1388-1394
- 377 Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era. **2021**, 10, 7909-7920 1
- 376 Early molecular imaging response assessment based on determination of total viable tumor burden in [Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [Lu]Lu-PSMA-617 radioligand therapy. **2021**, 1 2
- 375 Efficacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer. **2020**, 70-82

- 374 Nanoparticles for Targeting of Prostate Cancer. **2020**, 26, 5393-5413 0
- 373 Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway. **2020**, 10, 584505 1
- 372 Alpha-therapy using radium-223 chloride in patients with castration-resistant prostate cancer. From clinical researches to routine practice. **2020**, 15, 84-92
- 371 Molecular mechanisms of docetaxel resistance in prostate cancer.. **2020**, 3, 676-685 1
- 370 Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study. **2020**, 61, 588-593 0
- 369 Taxane induces attenuation of the CXCR2/BCL-2 axis and sensitizes prostate cancer to platinum-based treatments.
- 368 Chemotherapeutic Agents for Urologic Oncology: Basic Principles. **2020**, 611-637
- 367 A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer. **2020**, 9, 23-26
- 366 ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. **2020**, B-1-B30-3
- 365 Principles of Chemotherapy in Older Adults. **2020**, 861-880
- 364 Taxanes – The Backbone of Medical Oncology. **2020**, 41, 221-234 0
- 363 Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone. **2020**, 44, 164-171
- 362 Impact of Serum γ -Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel. **2021**, 13, 1
- 361 Efficacy of Combination Chemotherapy With Docetaxel, Estramustine and Carboplatin in Men With Castration-resistant Prostate Cancer.. **2021**, 1, 451-457 0
- 360 Image enhancement methods on extracted texture features to detect prostate cancer by employing machine learning techniques. 1-25
- 359 Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer. **2020**, 16, 82-96
- 358 Chemotherapy in Prostate Cancer. **2005**, 83-94
- 357 Therapeutic Options for Benign Prostate Hyperplasia (BPH) and Prostatic Cancer. **2006**, 535-550

- 356 Vinorelbine, Doxorubicin, and Prednisone in Hormone Refractory Prostate Cancer. **2008**, 557-564
- 355 Gene Therapy for Advanced Prostate Cancer. **2007**, 139-163
- 354 Targeted Therapies for Prostate Cancer. **2008**, 263-290
- 353 Neurologic Complications of Genitourinary Cancer. **2008**, 459-480
- 352 New Perspectives on Chemotherapy in Prostate Cancer. **2008**, 401-425
- 351 Chemotherapy in Prostate Cancer. **2007**, 50-74
- 350 M \acute{e} tastases vertbrales des cancers prostatiques. **2007**, 179-184
- 349 Tumeurs urologiques du sujet g \grave{e} re. **2007**, 165-178
- 348 Prostatakarzinom. 1051-1078
- 347 Choices for surgery. **2007**, 175, 163-78
- 346 Non-Germ-Cell Genitourinary Tract Tumors. **2007**, 249-257
- 345 Prostatakarzinom. **2014**, 513-676 o
- 344 Chemotherapy and Prostate Cancer. **2021**, 105-118
- 343 New Advances in Radioimmunotherapy for the Treatment of Cancers. **2021**, 563-585
- 342 Sequence Inversion to Facilitate Concurrent Radiotherapy and Systemic Therapy. A Proof of Principle Study in the Setting of a Phase II Randomized Trial in Prostate Cancer. **2020**, 10, 570660
- 341 Anti-androgens induce Rab11a-exosome secretion in prostate cancer by suppressing amino acid-sensitive PAT4-mTORC1 signalling. 1
- 340 Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-na \acute{i} ve prostate cancer cells. **2020**, 12, 17694-17712 o
- 339 Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives. **2020**, 15, 168-180

- 338 The future in advanced prostate cancer: take your partners or is the last dance for me?. **2004**, 6 Suppl 10, S29-44 1
- 337 Prostate cancer update: 2004: highlights from the 4th international prostate cancer congress, grand bahama island, bahamas, july 15-18, 2004. **2005**, 7, 41-5
- 336 Dawning of the age of chemotherapy for prostate cancer. **2005**, 7, 110-2
- 335 Translation research in prostate cancer. **2006**, 8, 89-91
- 334 Recent Progress in the Treatment of Advanced Prostate Cancer With Intermittent Dose-Intense Calcitriol (DN-101). **2007**, 9, 1-8 4
- 333 Clinical experience with gene therapy for the treatment of prostate cancer. **2007**, 9 Suppl 1, S20-8 1
- 332 Current standard and investigational approaches to the management of hormone-refractory prostate cancer. **2007**, 9 Suppl 1, S9-S19 3
- 331 High-risk, clinically localized prostate cancer: is monotherapy adequate?. **2007**, 9 Suppl 2, S19-27 4
- 330 New paradigms for advanced prostate cancer. **2007**, 9 Suppl 2, S3-S12 20
- 329 Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?. **2007**, 5A, 151-160 12
- 328 Approach to primary care follow-up of patients with prostate cancer. **2008**, 54, 204-10 4
- 327 Satraplatin in the treatment of hormone-refractory metastatic prostate cancer. **2007**, 3, 877-83 7
- 326 Targeting the Androgen Receptor by Taxol in Castration-Resistant Prostate Cancer. **2010**, 2, 1-5 22
- 325 A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. **2010**, 2, 402-11 52
- 324 Prognostic factors for failure after prostatectomy. **2010**, 2, 1-19 23
- 323 Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. **2011**, 36, 197-202 68
- 322 The role of taxanes in the management of gastroesophageal cancer. **2011**, 2, 240-9 19
- 321 Cabazitaxel (jevтана): a novel agent for metastatic castration-resistant prostate cancer. **2012**, 37, 440-8 16

320	The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients. 2012 , 37, 453-63	1
319	Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer. 2013 , 38, 23-6	11
318	Management of metastatic castration-resistant prostate cancer. 2011 , 6, 90-96	1
317	Targeting bone physiology for the treatment of metastatic prostate cancer. 2013 , 11, 134-43	8
316	Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options. 2014 , 39, 130-43	6
315	Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases. 2013 , 6, 307-16	8
314	(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. 2015 , 5, 72-82	15
313	F10 Inhibits Growth of PC3 Xenografts and Enhances the Effects of Radiation Therapy. 2014 , 2,	10
312	Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis. 2015 , 8, 3465-73	10
311	Role of PARP-1 in prostate cancer. 2015 , 3, 1-12	13
310	Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer. 2015 , 8, 185-95	15
309	The HSP90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells. 2015 , 5, 3198-209	4
308	Translating insights of AR signaling from mouse models. 2013 , 2, 197-201	
307	Sipuleucel-T for the Treatment of Patients With Metastatic Castrate-resistant Prostate Cancer: Considerations for Clinical Practice. 2015 , 17, 203-10	11
306	Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'?. 2014 , 28, 974-80	13
305	A metastatic castration resistant prostate cancer patient with multiple bone metastases has durable biochemical and radiological response to docetaxel chemotherapy. 2016 , 4, 28-31	1
304	High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. 2016 , 5, 12-22	7
303	Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer. 2016 , 13, 151-60	11

302	microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1). 2017 , 9, 3599-3610	25
301	Synergistic Anticancer Effect of Paclitaxel and Noscapine on Human Prostate Cancer Cell Lines. 2017 , 16, 1432-1442	13
300	A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer. 2018 , 17, 17-37	2
299	Treatment of Advanced Prostate Cancer. 2018 , 115, 156-161	6
298	Prostate Cancer Academy 2019 Selected Summaries. 2019 , 21, 166-171	
297	Oncoxin-Viusid may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments. 2021 , 14, 5	1
296	Targeting treatment options for castration-resistant prostate cancer. 2021 , 9, 101-120	4
295	Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer-a narrative review. 2021 , 10, 3188-3198	0
294	[Clinical efficacy of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer]. 2021 , 53, 686-691	
293	Epigenetics and precision medicine in prostate cancer. 2022 , 69-108	
292	Prostatakarzinom. 2022 , 314-327	
291	A signal processor made from DNA assembly and upconversion nanoparticle for pharmacokinetic study. 2022 , 42, 101352	2
290	Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy. 2021 ,	0
289	Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC). 2021 , 82, 269	0
288	Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer.. 2021 , 12, 1009-1022	0
287	Optimizing sgRNA to Improve CRISPR/Cas9 Knockout Efficiency: Special Focus on Human and Animal Cell. 2021 , 9, 775309	3
286	Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. 2021 , 11, 778858	1
285	Disparities in germline testing among racial minorities with prostate cancer. 2021 ,	3

- 284 Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. **2021**, JCO2100728 3
- 283 Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. **2021**, 1 2
- 282 Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. **2021**, 23, 477-488
- 281 Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. **2021**,
- 280 The modern therapeutic & imaging landscape of metastatic prostate cancer: a primer for radiologists. **2021**, 47, 781
- 279 Clinical characteristics and outcomes for patients with non-metastatic castration-resistant prostate cancer. **2021**, 11, 22151 0
- 278 Patient Preference or Indifference: Learning from the CABADOC Study. **2021**, 81, 241-241
- 277 El índice nutricional pronóstico como factor pronóstico independiente para la respuesta al tratamiento, la supervivencia y la elección del fármaco en el cáncer de próstata metastásico resistente a la castración tratado con acetato de abiraterona o enzalutamida. **2021**,
- 276 Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. **2021**, 4
- 275 Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. **2021**, 12, 7033 4
- 274 Progress in Clinical Application of Abiraterone in the Treatment of mCRPC. **2021**, 11, 5507-5513
- 273 Identification of potential driving genes in prostatic cancer using complex network analysis. 1-6 1
- 272 The prostate cancer landscape in Europe: Current challenges, future opportunities. **2021**, 3
- 271 Association between Grade 4 Neutropenia and Abnormal Liver Function Test Values after Initial Administration of Docetaxel for Prostate Cancer Patients. **2020**, 46, 647-654
- 270 Oncoxin-Viusid[®] may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments. **2020**, 14, 1-1 1
- 269 Nuclear medicine therapy of prostate cancer: State of the art and future perspectives. **2021**,
- 268 Systemtherapie des mCRPC. **2021**, 339-360
- 267 Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with Abiraterone or Enzalutamide. **2021**, 1

266	Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancerâ narrative review. 2021 , 10, 3188-3198	1
265	Report on History of FDA and NMPA and Traditional and Future Methods of Treating Cancer. 2021 ,	
264	Metastatic Prostate Cancer: Treatment Options. 2021 , 1-12	5
263	Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer.. 2022 , 3, 205-213	0
262	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT.. 2021 , 22,	3
261	Bone Health Management. 2022 , 179-196	
260	Prostate cancer immunotherapy.. 2022 , 1-14	2
259	Safety and Efficacy of Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing Radium-Dichloride.. 2022 , 14,	1
258	Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors.. 2022 , 5, 83-90	
257	Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells.. 2022 , 37, 542-553	1
256	Treatment of Metastatic Hormone-Sensitive Prostate Cancer. 2022 , 97-117	
255	Combined effect of heat shock protein inhibitor geldanamycin and free radicals on photodynamic therapy of prostate cancer.. 2022 ,	1
254	Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD.. 2022 ,	
253	Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [Lu]Lu-PSMA I&T.. 2022 , 14,	1
252	Rational Second-Generation Antiandrogen Use in Prostate Cancer.	1
251	Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer.. 2022 , 14,	3
250	A Post-Marketing Surveillance Study to Evaluate the Safety Profile of Alvotere (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy.. 2022 , 96, 100659	0
249	Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer.. 2022 , 14,	2

248	Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus.. 2022 , 1	
247	Prognostic significance of risk stratification in CHARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer.. 2022 , 10, 7-13	0
246	Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis.. 2021 , 12, 789319	0
245	Radiotherapy for Advanced Prostate Cancer. 2022 , 197-213	0
244	A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.. 2022 ,	0
243	Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.. 2022 , 20, 48	0
242	Evaluation of JQ1 Combined With Docetaxel for the Treatment of Prostate Cancer Cells in 2D- and 3D-Culture Systems.. 2022 , 13, 839620	3
241	Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.. 2022 ,	1
240	Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer - Narrowing the Gap Between Bench and Bedside.. 2022 , 13, 842038	0
239	Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/- Docetaxel.. 2022 , 14,	1
238	Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer.. 2022 ,	
237	Clinical response in metastatic castration-resistant prostate cancer (mCRPC) cases treated with supra-physiological doses of testosterone: Bipolar androgen therapy.. 2022 , 10, e05433	0
236	Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?. 2022 , 14, 17588359221086827	
235	Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial.. 2022 , 22, 177	1
234	Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada.. 2022 ,	
233	Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer.. 2022 , 14,	2
232	PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?. 2022 , 14,	2
231	Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer.. 2022 ,	2

230	mCRPC patients receiving Ac-PSMA-617 therapy in post androgen deprivation therapy setting: Response to treatment and survival analysis.. 2022 ,	2
229	Comparison of 2-Weekly and 3-Weekly Dosing of Docetaxel in Metastatic Prostate Cancer.. 2022 ,	0
228	Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.. 2022 , 14, 673-686	0
227	Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number.. 2022 , 17, 5	
226	Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference.. 2022 , 29, 16	0
225	Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.. 2022 ,	0
224	Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?. 2022 , 13, 843110	0
223	Matched-pair analysis of [Lu]Lu-PSMA I&T and [Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.. 2022 , 1	0
222	The Dual Role of USP11 in Cancer.. 2022 , 2022, 9963905	0
221	Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.. 2022 , 14,	2
220	Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC.. 2022 , 14,	1
219	Prostate Cancer and Sleep Disorders: A Systematic Review.. 2022 , 14,	0
218	Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.. 2022 ,	0
217	Solamargine Inhibits Prostate Cancer Cell Growth and Enhances the Therapeutic Efficacy of Docetaxel via Akt Signaling.. 2022 , 2022, 9055954	0
216	Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials.. 2022 , 14, e22942	0
215	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer.. 2022 , 1	
214	MetastamiRs: The Role of MicroRNAs in the Metastatic Phenotype of Prostate Cancer.	
213	Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).. 2022 , 10,	2

212	Inflammatory molecules facilitate the development of docetaxel-resistant prostate cancer cells in vitro and in vivo.. 2022,	0
211	Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan.. 2022, 1	1
210	Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image-Guided Intensity-Modulated Radiotherapy for Localized High-Risk Prostate Adenocarcinoma. 2022, 100935	
209	Development of a bayesian toxo-equivalence model between docetaxel and paclitaxel.. 2022, 25, 104045	
208	Recent Advances in Medical Therapy for Urological Cancers.. 2022, 12, 746922	2
207	Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial.. 2022,	0
206	First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry.. 2022, 3008916221079662	
205	Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.. 2022,	4
204	Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer.. 2022, 14,	0
203	Hematologic toxicity profile and efficacy of [Ac]Ac-PSMA-617 β -radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer.. 2022, 1	0
202	Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer.. 2022, 82, 31-31	0
201	Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer.. 2021, OP2100480	0
200	Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authorsâ experience. 2021, 130-136	
199	Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer.. 2021, 14,	4
198	Descriptive study on burden and communication of fatigue among castration-resistant prostate cancer patients in Japan.. 2021, 1-10	
197	Current androgen receptor antagonists under investigation for resistant prostate cancer.. 2021, 1-12	1
196	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives.. 2021, 14,	
195	Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.. 2021,	1

- 194 Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer.. **2021**, 61, 2
- 193 Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?. **2021**, 14, 1
- 192 The Mangrove-Derived Diterpenoid Diaporthe B Inhibits the Stemness and Increases the Efficacy of Docetaxel in Prostate Cancer PC-3 Cells. **2021**, 16, 1934578X2110496
- 191 Insights of RKIP-Derived Suppression of Prostate Cancer.. **2021**, 13, 1
- 190 GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol).. **2022**, 14, 17588359221092486
- 189 Prostate diseases. **2022**, 1136-1152
- 188 A phase Ib/II study of the CDK 4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer.. **2022**, 2
- 187 Translational Strategies to Target Metastatic Bone Disease.. **2022**, 11,
- 186 Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits.. **2022**, 34, 100431 1
- 185 Overexpression of Nucleolin and Associated Genes in Prostate Cancer.. **2022**, 23, 1
- 184 A Phase 1b/2 Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men With Metastatic Castration-Resistant Prostate Cancer with Progression on an Androgen Receptor Targeting Agent.. **2022**, 3
- 183 Signs and symptoms in relation to progression, experiences of an uncertain illness situation in men with metastatic castration-resistant prostate cancer-A qualitative study.. **2022**, e13592
- 182 DataSheet_1.docx. **2020**,
- 181 DataSheet_2.docx. **2020**,
- 180 Data_Sheet_1.docx. **2020**,
- 179 Image_1.pdf. **2020**,
- 178 Image_2.pdf. **2020**,
- 177 Data_Sheet_1.docx. **2019**,

176 Image_1.tif. **2020**,

175 Image_2.tif. **2020**,

174 Image_3.tif. **2020**,

173 Image_1.TIF. **2020**,

172 Image_2.TIF. **2020**,

171 Image_3.TIF. **2020**,

170 Image_4.TIF. **2020**,

169 Image_1.jpg. **2018**,

168 Table_1.DOCX. **2018**,

167 Data_Sheet_1.ZIP. **2020**,

166 Image_1.TIF. **2020**,

165 Image_2.TIF. **2020**,

164 Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.. **2022**, 1

1

163 Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.. **2022**, 1-32

162 Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).. **2022**, JCO2102517

0

161 WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?. **2019**, 58, 36-41

160 The Holistic Approach to Cancer Pain Management.. **2022**, 91, 45-49

159 Psychosocial Stress, Glucocorticoid Signaling, and Prostate Cancer Health Disparities in African American Men.. **2020**, 4,

- 158 Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. **2022**, 1-55
- 157 Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer.. **2022**,
- 156 Lower fracture rates in patients treated with Radium-223, abiraterone or enzalutamide, when given concurrently with bone health agents: A real world analysis. **2022**, 1
- 155 Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors.. **2022**, 6, e2100461
- 154 Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy-Do We Know the Proper Way of Management?. **2022**, 14,
- 153 PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.. **2022**, 1 ○
- 152 The role of chemotherapy in metastatic prostate cancer.. **2022**, 32, 292-301 ○
- 151 Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer.. **2022**, 12, 7319
- 150 Pharmacoeconomic evaluation of using enzalutamide for treatment of patients with metastatic hormone-sensitive prostate cancer. **2022**, 18, 90-105
- 149 Prostate Cancer. **2022**, 355-370
- 148 Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review. **2022**, 11, 2783 ○
- 147 Increased fracture risk in prostate cancer: causes and consequences. **2022**, 13, 6-10
- 146 Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. **2022**, 14, 2470 ○
- 145 A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months.. **2022**, ○
- 144 Diagnosis and treatment of metastatic prostate cancer. **2022**, 23-47
- 143 Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide. **2022**, 13,
- 142 Repurposing of Metabolic Drugs and Mitochondrial Modulators as an Emerging Class of Cancer Therapeutics with a Special Focus on Breast Cancer.
- 141 Current Trends in Advanced Prostate Cancer Medical Setting. **2022**, 76, 168-180

- 140 PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications. **2022**, 82, 4
- 139 Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations. **2022**, 63, 823-829 0
- 138 Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer. 13, 0
- 137 Prostate and testicular cancer. **2023**, 319-326
- 136 Ubiquitin specific peptidase 11 as a novel therapeutic target for cancer management. **2022**, 8, 0
- 135 ¿Es el intervalo libre de docetaxel un factor predictivo para el cáncer de próstata resistente a la castración?. **2022**,
- 134 Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. **2022**, 7, 4
- 133 Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. 1
- 132 Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. 0
- 131 Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial. **2022**, 1
- 130 Is docetaxel-free interval a predictive factor for castration-resistant prostate cancer?. **2022**,
- 129 Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719). 2
- 128 Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
- 127 An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective. **2022**, 22,
- 126 Sex Differences in Taxane Toxicities. **2022**, 14, 3325 0
- 125 Assessment of chemotherapy-induced neurotoxicity using a point-of-care nerve conduction study device. 0
- 124 Current concepts of neuroendocrine cancer of the prostate: a clinical case and review of the literature. **2022**, 24, 242-249
- 123 circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3. **2022**, 10, 0

122	Microwell-based flow culture reduces hypoxia-induced phenotype and restores drug response in prostate cancer spheroids.	
121	Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer.	
120	Emerging Biomarker-Guided Therapies in Prostate Cancer. 2022 , 29, 5054-5076	2
119	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. 2022 , 7, 100518	0
118	Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.	
117	Systemic Treatments and Related Side Effects in Prostate Cancer. 2022 , 301-310	
116	Integrating pharmacogenomics data-driven prediction with bulk and single-cell RNAseq to demonstrate the efficacy of an NAMPT inhibitor against aggressive, taxane-resistant, and stem-like cells in lethal prostate cancer.	
115	Rupture of liver metastasis in high-volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy.	
114	Active Targeting of P-Selectin by Fucoïdan Modulates the Molecular Profiling of Metastasis in Docetaxel-Resistant Prostate Cancer. 2022 , 20, 542	1
113	The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. 2022 , 23, 8535	2
112	A Systematic Review and a Meta-analysis of Randomized Controlled TrialsâControl Groups in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).	0
111	Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer. 2022 , 29, 2705-2712	0
110	Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis. 2022 ,	0
109	Up-regulation of secretory leukocyte protease inhibitor in human samples might have a potential role of predicting prostate cancer recurrence and progression after surgery and hormonal therapy.	
108	Enhancing nanoparticle accumulation in two dimensional, three dimensional, and xenograft mouse cancer cell models in the presence of docetaxel. 2022 , 12,	2
107	Factors influencing survival in metastatic castration resistant prostate cancer therapy.	0
106	Resistance to prostate cancer treatments.	1
105	miRNAs in prostate cancer: Intercellular and extracellular communications.	1

104	Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience.	0
103	A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. 2022 , 175, 110-119	1
102	Current progress of nanomedicine for prostate cancer diagnosis and treatment. 2022 , 155, 113714	1
101	Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer. 2022 , 6, 100065	0
100	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. 2022 , 1-55	0
99	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. 2022 , 1023-1075	0
98	References. 2023 , 113-141	0
97	Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. 2022 ,	3
96	Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.	0
95	Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer. 2022 , 2, 273-284	0
94	PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures. 2022 , 14, 4751	1
93	Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer. 2022 ,	0
92	Bibliometric analysis of the global research development of bone metastases in prostate cancer: A 22-year study. 12,	0
91	Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs. Volume 14, 339-350	1
90	Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patientâs CDK12 Mutation: A Case Report. Volume 15, 947-952	1
89	Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer. 2022 , 12,	0
88	Bone Health Management in the Continuum of Prostate Cancer Disease. 2022 , 14, 4305	1
87	A self-microemulsion enhances oral absorption of Docetaxel by inhibiting P-glycoprotein and CYP metabolism.	0

- 86 Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells. **2022**, 14, 4626 1
- 85 Emerging hormonal agents for the treatment of prostate cancer. 1-9 0
- 84 Systemtherapie des metastasierten Prostatakarzinoms. **2022**, 43, 523-529 0
- 83 A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications. **2022**, 6, 100084 0
- 82 Palliative Therapy of Bone Metastases. 0
- 81 Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. 0
- 80 Neoplasms of the Prostate. 1-46 0
- 79 Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men. **2022**, 14, 4822 0
- 78 Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer. **2022**, 0
- 77 UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer. **2022**, 0
- 76 Knockdown of USP8 inhibits prostate cancer cell growth, proliferation, and metastasis and promotes docetaxel activity by suppressing the NF-κB signaling pathway. 12, 0
- 75 Juglone promotes antitumor activity against prostate cancer via suppressing glycolysis and oxidative phosphorylation. 0
- 74 Dynamics of antioxidant heme oxygenase-1 and pro-oxidant p66Shc in promoting advanced prostate cancer progression. **2022**, 193, 274-291 0
- 73 Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. **2022**, 23, 1398-1408 0
- 72 The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations. 1-12 0
- 71 New NNN pincer copper complexes as potential anti-prostate cancer agents. **2022**, 244, 114859 0
- 70 Analysis of aberrant miRNA-mRNA interaction networks in prostate cancer to conjecture its molecular mechanisms. **2022**, 1-13 0
- 69 The efficacy of sequential therapy with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan. 0

68	Biomolecule-functionalized nanoformulations for prostate cancer theranostics. 2022 ,	1
67	Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel. 12,	0
66	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance. 2022 , 32, 1373-1419	0
65	Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide. 030089162211325	0
64	The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.	0
63	Metastatic castrate-resistant prostate cancer: a new horizon beyond the androgen receptors. 2022 , 16, 223-229	0
62	Prostatakarzinom: palliative Therapie. 2022 , 1-24	0
61	Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study.	0
60	Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer. 2022 , 23, 269-274	0
59	The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review. 2022 , 2022, 1-18	0
58	Incidence and predictors of febrile neutropenia in patients with metastatic castrate- resistant prostate cancer receiving docetaxel.	0
57	Methodological and reporting standards for quality of life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. 2022 ,	0
56	Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer. 2022 , 12,	0
55	Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis. 2022 , 29, 9511-9524	0
54	Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer. 2022 , 14, 6009	0
53	Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition. 2023 , 12,	0
52	The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer.	0
51	A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer (CRPC) and skeletal metastases. 2022 ,	0

- 50 Access of new systemic therapies for Genito-urinary cancers in low-middle income countries. 2, ○
- 49 Clinical and pharmacoeconomic aspects of the use of prolonged colony-stimulating factors. **2022**, 112-118 ○
- 48 A self-microemulsion enhances oral absorption of docetaxel by inhibiting P-glycoprotein and CYP metabolism. ○
- 47 Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors. ○
- 46 Abiraterone and Docetaxel Treatments Increase Phospho-PTEN Expression in Metastatic Prostate Cancer Cells. **2023**, 13, 6-10 ○
- 45 Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in Prostate Cancer by Low-Intensity Focused Ultrasound. **2023**, 24, 825 ○
- 44 The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer. 12, 1 ○
- 43 The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer. ○
- 42 Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH. ○
- 41 Novel Specific Pyruvate Kinase M2 Inhibitor, Compound 3h, Induces Apoptosis and Autophagy through Suppressing Akt/mTOR Signaling Pathway in LNCaP Cells. **2023**, 15, 265 ○
- 40 Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines. **2023**, 24, 666 ○
- 39 Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells. **2023**, 15, 902 ○
- 38 Emerging systemic treatment for metastatic castration-resistant prostate cancer: a review of recent randomized controlled trials. Publish Ahead of Print, ○
- 37 Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. 41, ○
- 36 Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). ○
- 35 Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. **2023**, ○
- 34 Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer. **2023**, 23, ○
- 33 Sympathetic α -adrenergic receptor blockade overcomes docetaxel resistance in prostate cancer. **2023**, 657, 69-79 ○

- 32 The Future of Radioligand Therapies in Metastatic Castrate-Resistant Prostate Cancer. **2023**, 3, 129-136 ○
- 31 Current therapy and drug resistance in metastatic castration-resistant prostate cancer. **2023**, 68, 100962 ○
- 30 Addressing the need for more therapeutic options in neuroendocrine prostate cancer. **2023**, 23, 177-185 ○
- 29 Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review. **2023**, ○
- 28 Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting. **2023**, 24, 2939 ○
- 27 Identification of Promising Drug Candidates against Prostate Cancer through Computationally-Driven Drug Repurposing. **2023**, 24, 3135 ○
- 26 Androgen deprivation therapy plus chemotherapy – androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer. ○
- 25 Prostate cancer and novel pharmacological treatment options – what’s new for 2022?. **2023**, 16, 231-244 ○
- 24 Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy. **2023**, ○
- 23 Enzalutamide-Induced Acute Maculopapular Rash in Treatment of Metastatic Prostate Cancer: First Case Report from a Tertiary Cancer Care Center of North India. ○
- 22 Geriatric Assessment Implementation before Chemotherapy in METastatic Prostate Cancer, Results from the Real-Life Study GAMERS. **2023**, 12, 1636 ○
- 21 Microtubule Inhibitors. 1-18 ○
- 20 Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients. **2023**, 13, ○
- 19 Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score. **2023**, 83, 688-694 ○
- 18 Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications. **2023**, 15, 1518 ○
- 17 Vaccines as treatments for prostate cancer. ○
- 16 Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells. **2023**, 24, 4923 ○
- 15 Cancer-Associated Fibroblast: Role in Prostate Cancer Progression to Metastatic Disease and Therapeutic Resistance. **2023**, 12, 802 ○

- 14 Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain. 1-14 ○
- 13 Radionuclide Therapies and Correlative Imaging. **2023**, 838-870 ○
- 12 Microwell-based flow culture increases viability and restores drug response in prostate cancer spheroids. 2200434 ○
- 11 First in man study: Bcl-XL_42-CAF α 09b vaccines in patients with locally advanced prostate cancer. 14, ○
- 10 Quantitative assessment of ^{99m}Tc-methylene diphosphonate bone SPECT/CT for assessing bone metastatic burden and its prognostic value in patients with castration-resistant prostate cancers: initial results in a single-center retrospective study. ○
- 9 The Applications of Mitoxantrone and Its Liposome in Adult Acute Myeloid Leukemia. **2023**, 13, 51-58 ○
- 8 Calcium signalling pathways in prostate cancer initiation and progression. ○
- 7 Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer. **2023**, 15, 901 ○
- 6 Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy. 10, 29-39 ○
- 5 Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14). 1-9 ○
- 4 Chemotherapy. **2023**, 7-159 ○
- 3 The Transcriptomic Profiles of ESR1 and MMP3 Stratify the Risk of Biochemical Recurrence in Primary Prostate Cancer beyond Clinical Features. **2023**, 24, 8399 ○
- 2 New developments in the management of newly diagnosed metastatic prostate cancer. **2023**, 14, 6-9 ○
- 1 The Intersection of Prostate Cancer and Hypertension: a Call to Action. ○